

**HOSPITAL CANCER REGISTRY
NATIONAL CANCER REGISTRY PROGRAM
INDIAN COUNCIL OF MEDICAL RESEARCH**

**ANNUAL REPORT
2021**

**CANCER INSTITUTE (W.I.A)
CHENNAI, INDIA
March 2024**

HOSPITAL CANCER REGISTRY #

ANNUAL REPORT: 2021

Dr. R. SWAMINATHAN M.Sc., Ph.D.

Principal Investigator,
Hospital and Population Based Cancer Registries, ICMR &
Professor & Head,
Division of Epidemiology, Bio-Statistics and Cancer Registry,
Cancer Institute (WIA), Chennai.

Dr. R. RAMA M.Sc., Ph.D.

Associate Professor & Senior Bio-Statistician,
Division of Epidemiology, Bio-Statistics and Cancer Registry,
Cancer Institute (WIA), Chennai.

Address for communication

Cancer Institute (W.I.A.),
38, Sardar Patel Road,
Chennai 600 036.
Tel : 91-44-22350131
Fax: 91-44-24912085
e-mail: contact@cancerinstitutewia.org

***# partly supported by the grant from National Cancer Registry Program,
Indian Council of Medical Research, New Delhi***

HOSPITAL CANCER REGISTRY STAFF

Associate Prof. & Senior Bio-Statistician

Dr. R.Rama, M.Sc., Ph.D.

Data Manager

Ms Kalyani M S, MBA

Section In-Charge (Training & Data Quality)

Ms. Shanthi.P., M.A, M.Phil, DPS (Retired in 2022)

Ms Vidhya J, M.A.

Social Investigator

Mr Thiyagarajan K, B.Sc

Ms Sahaya Delma C, B.A. Dip.SW

Ms Bhuvaneswari S, B.Sc.

Ms Devi N, M.Sc., M.Ed

Ms Divya S, BE (Resigned in 2024)

Ms Swetha R, B.Sc.

Ms Malar U, B.A. Sociology

Ms Ragasumithra S, B.Com.

Ms Hemavathi A, MSW (Resigned in 2024)

Ms Ramya R, B.Sc.

Mr Ajith P, M.Sc., B.Ed.

Assistant

Mr Sivakumar P, M.Sc.

Ms Deepa Ramani, B.A., PGDSE

Ms Thahirunnisa S, M.Com.

Data Entry Operator

Ms Deepa E, B.Sc.

Ms Bagyalakshmi P, B.Com.

Ms Mageshwari A, B.Sc. (Resigned in 2023)

Ms Bhuvana T K. (Resigned in 2023)

Ms Keerthika R, B.Sc

Ms Sathya N, B.Sc., B.Ed.

Ms Tamilselvi M, B.Sc.,

Typist

Ms. C. Deepa, B.A.

Medical Record Assistant

Mr Rajagopal R, HSLC
Ms Maheswari V, B.B.A.
Mr Venkatesh R, B.Com.
Ms Mohana G, B.A.
Ms Sobhana V R, HSLC
Ms Dharanya G, B.Sc
Ms Kaviya V, B.Sc.
Mr Parthipan E, M.A., B.Ed.,
Mr Adarsh Kumar B, I.T.I.

ACKNOWLEDGMENT

The team of the ICMR Hospital Cancer Registry project gratefully acknowledges the entire contingent of non-ICMR project staff of the Division of Epidemiology and Cancer Registry at the institute for their understanding, cooperation and contribution towards data collection without which this report would not have been a reality. The consultancy services offered by the clinical fraternity of the institute in resolving the queries in the medical record are greatly appreciated.

CONTENTS

Topic	Page No.
Summary	1
Introduction	2
Hospital Based Cancer Registry at Cancer Institute (WIA)	5
Cancer Registration and Follow-up at the Institute	6
Data collection & Processing	8
Burden of cancer	9
Distribution of cases registered & provisionally diagnosed as cancers	11
Burden of new registrants 2021	13
Regionwise distribution of new registrants	14
Cancer cases by age group	15
Leading cancers	16
Common cancers cases by age group & gender	17
Most valid basis of diagnosis	19
Clinical extent of disease	20
Cancer directed treatment	22
Childhood cancers	22

Descriptive statistics & survival by site

Tongue	23
Mouth	24
Hypopharynx	25
Oesophagus	26
Stomach	27
Colon & Rectum	28
Larynx	29
Lung	30
Female Breast	31
Cervix	32
Vulva, Vagina & Others	33
Corpus Uteri	34
Ovary	35
Penis	36
Lymphoma	37
Leukemia	38
Childhood cancers	39
Tobacco Related Cancers	40

List of Appendices	41
--------------------	----

SUMMARY

New registrants at the institute during 2021, were 13,688 with a sex ratio of 1,214 females to 1000 males. 86% of attendances were from Tamil Nadu. Invasive cancer [ICD-10: C00-C96] was made in 10,056 (Male: 4,787; Female: 5,269) with a sex ratio of 1,101 females to 1,000 males. The median age at diagnosis was 54 years for both sexes.

Mouth cancer (11.9%) continues as leading cancer among men since the inception in 1984. Breast cancer (30.4%) emerged as the leading cancer among female cancers. Cervix cancer which was the leading cancer among female in 1984 is now in the second position.

In 0-19 age group leukemia emerged as the commonest cancer among both sexes. Leukemia (20.0%) was the leading cancer among males and breast (22.6%) among females in the age group 20-34. The top two cancers were mouth (14.7%) and tongue (11.7%) among males; the order is breast (33.7%) followed by cervix (15.1%) among females in the age group 35-64. In the geriatric age group (65+ years) lung (10.8%) was the leading site of cancer among males followed by stomach (9.1%); it was breast (23.7%) followed by cervix (12.0%) among females.

90.5% of cases were microscopically confirmed. Among microscopically verified cases 88.7% were proved by primary histology. Majority of the cases were locally advanced cancers (47.4%). Treatment was administered in 37.5% of the patients registered. Patients were treated predominantly by chemotherapy.

Leukemia and Lymphoma constituted 50.7% of childhood cancers followed by bone tumors (21.4%). The order of cancers by histology type were Acute lymphoid leukemia (25.5%), Osteosarcoma (12.8%), Acute myeloid leukemia (8.7%), Ewing sarcoma (7.8%), Hodgkins lymphoma (7.0%), Chronic myeloproliferative disease (4.6%) of all childhood cancers.

Descriptive statistics on major cancer sites for the year 2021 and overall survival percentages at 5 years from diagnosis on these sites for the years 2017-18 followed till 31st Dec 2022 establishes the strength of the Hospital Cancer Registry at the Institute.

Introduction

Cancer Institute (W.I.A) at Adyar, Chennai founded in the year 1954 is recognized as Regional Centre for Cancer (RCC) and State Cancer Institute. It is a center for clinical, applied and fundamental research from prevention, causation, detection, diagnosis, treatment, rehabilitation to palliation for cancer.

This 576 in-patient beds comprehensive cancer hospital offering multi-modality treatment with state-of-art facility from diagnosis to treatment is a public charitable voluntary not-for-profit institution where treatment is offered equally to all patient irrespective of his / her social or economic status.

National Accreditation Board for Hospitals & Healthcare providers-NABH, under the Quality Council of India, has granted accreditation to the Cancer Institute (W.I.A) since 2019

Cancer Institute comprises of 4 components:

1. **Hospital:** Clinical consultation is done in cubicles of Surgical, Radiation, Medical, Breast and Gynecology with ancillary facilities for diagnosis (Blood Bank, Radio-imaging, Onco-pathology, Biochemistry, Microbiology), Medical Physics, Anesthesia, Rehabilitation (Physiotherapy) etc. Psychology counseling for patients are done by Psycho-oncology Department. House visits are also undertaken to supportive care patients on pain & palliation. Mahaveer Ashray admits terminally ill patients. **Dharmasala:** Patients waiting for admission is now boarded and lodged by the Cancer Institute (W.I.A). Average occupancy is 160, one patient with one attendant. Food and accommodation is provided totally free.

2. Research: Research activities conducted at the institute follow ethical guidelines in both clinical and non-clinical backgrounds.

Ethics Committee: Eminent persons from the Medical, scientific, non-medical and non-scientific fields are members Institutional Ethics Committee (IEC). They ensure the protection of the rights, safety and well-being of human subjects enrolled in a clinical trial. After approval of the project the committee reviews and monitors trials on regular basis.

Molecular Oncology: Department of Molecular Oncology commenced work in 1994 on the common cancers in this part of the world – namely cervical, breast, gastric cancers as well as on hereditary cancers. The Department has been recognised as a Centre of Excellence by the Dept. of Science and Technology [DST], Govt of India. and has received grants from governmental agencies (DST, Dept of Biotechnology, Govt of India [DBT], Indian Council of Medical Research [ICMR]), Private Foundations like Chennai Willingdon Corporate Foundation and International funding from WHO.

Clinical Research: Research activities that are conducted by the various clinical departments like Medical Oncology, Surgical Oncology, Radiation Oncology, Anaesthesia, Palliative Medicine etc. Clinical trial ward consisting of 20 bed. Both investigator initiated and regulatory pharmaceutical trials are conducted. Our Institute is recognised by Department of Biotechnology, Government of India funding under the BIRAC (Biotechnology Industry Research Assistance Council) for the development of the clinical research unit.

- 3. Prevention:** Cancer control initiatives started as early as 1961. Cancer control by early detection and cancer screening services for apparently healthy people has been part of the services rendered by the institute. Community based screening programs are undertaken at Chennai, Manali, Villupuram, Gummidipoondi, Pudukkottai & Thiruvannamalai. Mamography for breast is done in Mammomobile van, Phone follow up of screened subjects and awareness was done by project staff.

Molecular diagnostics and cancer biology department established in 2013 focuses on integrated aspects of cancer genomics and precision oncology with focus on prevention based activities.

Epidemiology, Biostatistics and Cancer Registry (EBCR): The divisions under EBCR are (i) Patient services - OPD counters, medical record with lifetime follow up, documentation and digitization, (ii) Hospital Cancer Registry (HCR), (iii) Population-Based Cancer Registry (PBCR) and (iv) Biostatistics & Epidemiology division. This department caters to the statistical needs of both hospital and population by their monthly and yearly patient accrual and dissemination of facts and figures.

- 4. College of Oncological Sciences** is recognized by The Tamil Nadu Dr. M.G.R. Medical University for conducting super-speciality training in Medical Oncology, Surgical Oncology and Radiation Oncology courses, Bachelor degree courses in Radiotherapy Technology, Radiology & Imaging Technology, Nuclear Medicine Technology and Anaesthesia Technology and Postgraduate course in Radiotherapy Technology. The college is also recognised by The Tamil Nadu Dr.M.G.R. Medical University and University of Madras for

conducting Ph.D, M.Phil courses and M.Sc. Medical Physics course by the Anna University.

At present 206 students are studying in various courses at the institute.

Hospital Based Cancer Registry at Cancer Institute (WIA)

The Hospital Based Cancer Registry at the institute is functioning since its inception in 1954. Socio-demographic and clinical data are documented in uniform specified formats. The hospital cancer registry is often a pre-requisite for hospital's research programme and the registry take concerted efforts to achieve the highest levels of data quality. This eases the location of particular information in case record for high resolution data abstraction. It is the responsibility of the hospital registry and MRD personnel to monitor the completeness of documentation in medical record and draw attention of clinicians to any shortcomings in appropriate hospital forums (tumour or specialty boards, etc.). The registry maintains records of all the treated patients since the inception of the institute. Physical medical records are maintained in the racks. Medical records of patients are scanned as per the hospital policy. Digital medical records are saved in the server for retrieval as and when required. Maintenance of records in digital format conserved the rack storage space and is also easy for retrieval.

Data collection on the lines suggested by the National Cancer Registry Program (NCRP) of Indian Council of Medical Research (ICMR) commenced from the year 1984. All the cancer cases reported at the institute are reported. Patterns of care and survival studies for specific cancers such as cancer of breast, cervix and head & neck was undertaken since 2006 by NCRP. This study extended to data abstraction of hematopoietic malignancy and other gynecologic malignancy during 2019.

Cancer Registration and Follow-up at the Institute

1. Out-Patient Department (OPD)

All new patients attending OPD are assigned serial Unique Hospital Identification Number (UHID) by the hospital Electronic Medical Record (EMR) software MedMantra. Social Investigator interviews and records in EMR the information of each patient on identity, socio-demographic and disease related information at presentation to the OPD. The UHID generated at this instance serves as the reference number for all subsequent visits, and the investigation raised, reports collection etc. can be viewed in the EMR.

Patients undergo clinical examination in the cubicles assigned by site of cancer (surgical, radiation, medical, breast and gynec). Based on the investigations and preferences for treatment the patient is further admitted for further invasive cancer directed intervention or treated as OP. The records of patients who were not admitted are filed separately classified as (a) not-cancer, (b) treated elsewhere and not suitable for further cancer directed treatment, (c) referred back to the institution where they had initial treatment or (d) advised supportive care.

2. In-Patient Department (IPD)

A docket is prepared for the patients admitted in the ward. All the OPD documents are assembled in the docket. In-depth details on socio-economic, life-style, family history, diet and habits are collected by social investigators and local condition of disease and treatment plan are documented by clinician. 5-7 addresses and telephone/mobile numbers of dear and near persons of the patient are collected with their consent so that they can be contacted for follow-up purpose.

Patients admitted to the ward for further cancer directed treatment has another number assigned which is a serial number generated by year and site of cancer. This number known as clinical index number (CIN) is the order by which the records are stored in the rack for easy retrieval of physical record. The UHID and CIN are unique to each patients and are interchangeably referred. HCR practices centralized medical records system. The registry maintains records of all the treated patients since the inception of the institute. Medical records are scanned and digital medical records are saved in the server for retrieval as and when required. Maintenance of records in digital format conserved the rack storage space and is also easy for retrieval.

All the events from the first OPD attendance to lifetime follow-up activities such as repeat admission, OPD visits and active follow-up are filled in the same docket.

3. Follow-up

Lifetime follow-up of patients treated at the institute is achieved by two methods.

1. Passive method - regular to follow up at the OPD and/or in regular correspondence with the hospital, "on their own" or the vital status of persons are made available by the linkage of data from the vital statistical division of the areas.
2. Active method – Defaulters of passive follow-up are contacted to attend OPD or know about their vital status by using any contact methods approved by the patients at the time of admission. The order of telephone active follow-up will be first the patients, spouse/parents/children, siblings, relative and friends. Next OPD appointment is assigned for patients requesting for appointment. Vital status, date and responder are noted for record purpose.

Disease status of patient is an important factor related with the clinical follow-up. Patients who are asymptomatic may be irregular to follow-up. The other case may be that the patient is on symptomatic/supportive case due to progression of the disease. In both the cases follow-up activity has to be undertaken because in the first instance it acts as a reminder whereas in the second it is important to document the vital status and date of the event. The Hospital Cancer Registry at the Cancer Institute (WIA) has demonstrated the effectiveness of its system in dealing with different groups of patients and its applicability in any setting. It only needs personnel from the registry to be dedicated exclusively for the purpose of dealing with follow up enquiry attempts and documentation.

Data Collection

Socio-demographic variables are entered in MedMantra. The personal identification details and the duration in stay at their usual residence along with district/area of the registered cases are mandatorily entered as it serves as the basis for population registries. Details of diagnosis if available are also entered in the EMR at the time of registration by trained social investigators. Clinical notes and investigative reports are either in electronic or printed formats for all the patients attending the institute. For treated patients separate docket in the chronology of their visit is documented. Data collection and abstraction is done on the NCRP, ICMR guidelines using the structured preprinted hospital cancer registry proforma. ICMR Coding Manual for Hospital Cancer Registries is followed for each data variable. International Classification of Diseases for Oncology, III edition (ICD_O-III) is followed for coding the topography and morphology. Only Invasive cancers are reported to the Co-ordinating Unit of the NCDIR, Bangalore.

Data Processing

Data pertaining to the Identification information and Basic demographic parameters are imported into the HBCRDM software from MedMatra EMR. The data submitted in the extended hospital based clinical care registry, patterns of care and survival is linked to the HBCR online portal. Confirmation uploaded information is done for proved cancer cases and further disease related information are entered and submitted online through the NCRP online portal. Quality checks on validity, consistency and duplication are made using the in-house developed computer programs on the data exported from the NCRP online portal. In addition, the CHECK program developed by the International Agency for Research on Cancer (IARC), Lyon, France, is run to check for possible inconsistencies involving the age at diagnosis, sex, site and morphology. The NCRP online range, unlikely, validity and consistency checks are scrutinized. Completed data is accessed by the Co-ordinating Unit of the NCRP at Bangalore for the preparation of the consolidated report. Reports giving the descriptive statistics on the frequencies of cancer by different covariates are published periodically.

Burden of cancer

New registrants during the period 1984-2023 were 4,75,941 and 3,25,975 (68.5%) were proved as cancers. 77.7% of registered cases were proved as cancer cases in 2023 as compared to 59.9% during 1984. Annual increase in the number of registered cases and cancer cases were 2.5% and 4% respectively over the period of 1984-2023. (Figure 1)

Female preponderance has been observed in the cancer cases and the gender ratio ranges between 1053-1204 females per 1000 male over the period 1984-2023. Annual increase in the number of males and females were 4.3% and 3.8% over the period of time. (Figure 2)

Figure 1: Trend of cases registered and cancer cases: 1984-2023





Figure 2: Trend of cancer cases registered by gender: 1984-2023




Distribution of new registered cases and provisionally diagnosed cancer cases in 2022 and 2023 are given below (Table 1)

Table 1: Distribution of cases registered and provisionally diagnosed as cancers: 2022 & 2023

ICD code	Cancer Site	2022		2023	
		Registered	Diagnosed	Registered	Diagnosed
C00	LIP	30	22	48	28
C01-02	TONGUE	625	517	578	514
C03-06	MOUTH	963	701	975	696
C07-08	SALIVARY GL	82	53	79	50
C09	TONSIL	45	38	52	51
C10	OTHER ORPHX	82	75	69	69
C11	NASOPHARYNX	68	46	71	42
C12-13	HYPHARYNX	227	207	202	223
C15	OESOPHAGUS	299	232	322	257
C16	STOMACH	758	656	737	613
C17	SMALL INTEST	12	27	7	37
C18	COLON	316	230	323	267
C19-20	RECTUM	378	365	354	331
C21	ANUS	54	45	36	29
C22	LIVER	352	267	357	269
C23-24	GALLBLAD ETC	122	126	138	157
C25	PANCREAS	178	163	218	171
C30-31	NOSE SINUS ETC	55	45	54	45
C32	LARYNX	234	144	231	166
C33-34	TRAC BRONC LUNG	720	589	762	623
C37-38	OT THORACIC ORG	40	27	49	28
C40-41	BONE	257	133	223	125
C43	MELANOMA SKIN	141	40	124	38
C44	OTHER SKIN	20	85	29	98
C47+49	CON & SOFT TISS	207	139	218	132
C50	BREAST	2254	1,544	2251	1530
C51	VULVA	27	27	18	12
C52	VAGINA	36	41	40	42
C53	CERVIX UTERI	1104	724	1141	714
C54	CORPUS UTERI	20	210	24	217
C56	OVARY	448	340	473	341
C57	OT FEMALE GENIT	2	10	1	16
C58	PLACENTA	1	3	3	3
C60	PENIS	55	55	59	52
C61	PROSTATE	197	175	206	185
C62	TESTIS	48	48	48	43
C63	OT MALE GENITAL	3	1		1
C64	KIDNEY	187	139	207	162
C65	RENAL PELVIS	3	0	3	3
C66	URETER	7	6	10	7
C67	URINARY BLADDER	171	139	167	146
C68	OTHER URINARY O	1	3	6	2
C69	EYE	22	21	28	25
C70-72	BRAIN NERVOUS S	271	167	250	166
C73	THYROID	265	198	312	232
C74-75	ADRL & OT ENDO	32	18	32	22
C77-C79	SEC OTHERS	158	183	125	157
C81	HODGKIN DISEASE	80	97	88	87
C82-85,96	NHL	468	261	490	286
C90	MULTIPLE MYELOM	133	113	152	140
C91	LYMPHOID LEUK	116	153	139	159
C92-94	MYELOID LEU	231	251	227	255
C95	LEU UNSPECIFIED	99	43	119	62
O&U	OT & UNCERTAIN	225	48	225	58
C00-C96	ALL SITES	12929	9990	13100	10184

Figure 3: Regionwise distribution of provisionally diagnosed cancers: 2022 & 2023



Patients from Tamil Nadu including Chennai and suburban areas constituted 85%-88% of cancer cases registered during 2022 and 2023. 7%-9% of cancer patients were from Andhra Pradesh and Telangana. 1% of cancer cases were from Puducherry. 0.5% of the cancer cases registered were from outside India.

This report is confined to cases either registered or diagnosed as invasive cancer for the first time at the Cancer Institute (W.I.A) between 1st January 2021 and 31st December 2021. The burden of new registrants at the institute during the calendar year of 2021 (Table 2), in terms of numbers is 13,688 with a sex ratio of 1,214 females to 1000 males.

Table 2 : Burden of new registrants 2021

Statistics for 2021	No of cases
Cases seen	1,53,211
New Registration	13,688
Not cancers	1,851
Opinion	909
Query cancers	856
Invasive cancers	10,056
Follow up	1,39,523
Admission/re admission	9,683

Table 3 : Regionwise distribution of cases registered: 2021

Region	No.	%
Tamilnadu	8597	62.8
Chennai City	3227	23.6
Andhra Pradesh	1183	8.6
Other States	324	2.4
Puducherry	150	1.1
Assam	81	0.6
Karnataka	52	0.4
Kerala	48	0.4
Outside India	26	0.2
Total	13688	100.0

The patients are drawn from different parts of India, the distribution of which is as follows: Chennai city and its suburbs (23.6%), other parts of Tamil Nadu (62.8%), Andhra Pradesh (8.6%), Kerala (0.4%), Assam and other north eastern states (0.6%), rest of India (2.4%) and other countries (0.2%) during the period of 2021 (Table 3). The average combined burden of new as well as old cases visiting the hospital for some intervention is 489 per day on an average.

86% of attendances were from Tamilnadu (Table 3). Proximity of the region to the hospital place a vital role on the attendances to the hospital. Chennai, Kanchipuram, Thiruvallur, Villupuram, Vellore and Tiruvannamalai contributed 61% of cases from Tamilnadu (Table 4 & Figure 4).

Out of the 13,688 registrants, a diagnosis of an invasive cancer [ICD-10: C00-C96] is made in 10,056 (Male:4,787; Female:5,269) with a sex ratio of 1,101 females to 1,000 males. 68.4% of the cancer cases were in the age group of 35-64 years. The median age at diagnosis was 54 years for both sexes (Table 5)

Table 5: Cancer cases in the broad age group by sex: 2021

Age group	Male		Female		Total	
	No.	%	No.	%	No.	%
00-19	217	4.5	128	2.4	345	3.4
20-34	350	7.3	354	6.7	704	7.0
35-64	2,995	62.6	3,879	73.6	6,874	68.4
65+	1,225	25.6	908	17.2	2,133	21.2
Total	4,787	100.0	5,269	100.0	10,056	100.0
Median age at diagnosis	56		52		54	
Range	(1-93)		(0-92)		(0-93)	

The distribution of cases by five-year age group revealed that the peak age group was 55-59 with 14.2%, 15.4% and 14.8% for male, female and both sexes together respectively (Table 6).

Table 6: Cancer cases in 5-year age group by sex: 2021

Age group	Male		Female		Total	
	No.	%	No.	%	No.	%
00-04	58	1.2	33	0.6	91	0.9
05-09	37	0.8	24	0.5	61	0.6
10-14	42	0.9	26	0.5	68	0.7
15-19	80	1.7	45	0.9	125	1.2
20-24	82	1.7	69	1.3	151	1.5
25-29	117	2.4	114	2.2	231	2.3
30-34	151	3.2	171	3.2	322	3.2
35-39	248	5.2	339	6.4	587	5.8
40-44	341	7.1	531	10.1	872	8.7
45-49	478	10.0	755	14.3	1233	12.3
50-54	577	12.1	809	15.4	1386	13.8
55-59	679	14.2	813	15.4	1492	14.8
60-64	672	14.0	632	12.0	1304	13.0
65-69	555	11.6	446	8.5	1001	10.0
70-74	388	8.1	278	5.3	666	6.6
75+	282	5.9	184	3.5	466	4.6
Total	4787	100.0	5,269	100.0	10056	100.0

Leading Cancers

Leading cancers constituted 63.7% of cases among men and 74.3% of cases among females during the year 2021 (Table 7). Mouth cancer (12%) continues as leading cancer among men since the inception in 1984. Breast cancer (30.5%) emerged as the leading cancer among female cancers. Cervix cancer which was the leading cancer among female in 1984 is now in the second position. This transition of the leading cancer among female took place in the year 2010

Table 7: Leading sites of cancers: 2021

Male			Female		
Leading sites	No.	%	Leading sites	No.	%
Mouth	572	11.9	Breast	1604	30.4
Tongue	430	9.0	Cervix	708	13.4
Stomach	428	8.9	Ovary	346	6.6
Lung	346	7.2	Stomach	216	4.1
Leukemia	302	6.0	Mouth	204	3.9
Lymphoma	226	5.0	Corpus uteri	203	3.9
Rectum	207	4.3	Lung	195	3.7
Liver	196	4.1	Leukemia	165	3.1
Esophagus	184	4.0	Tongue	139	2.6
Hypopharynx	163	3.4	Lymphoma	136	2.6

Common cancers by broad age group and gender (Table 8)

Paediatric age group (0-19 years)

Leukemia emerged as the commonest cancer and bone cancers ranked second among both sexes in this age group while the rank order later on displayed a varied pattern. A separate section on childhood cancers follows later.

Young adults (20-34 years)

The commonest cancer is leukemia (20.0%) among males and breast (22.6%) among females in this age group.

35-64 years

The top two cancers are mouth (14.7%) and tongue (11.7%) among males; the order is breast (33.7% followed by cervix (15.1%) among females.

Geriatric age group (65+ years)

Lung (10.8%) is the leading site of cancer among males followed by stomach (9.1%); it is breast (23.8%) followed by cervix (12.0%) among females in the geriatric group.

Table 8: Common cancers by broad age group and gender: 2021

Leading site of cancer in the age group 0-19 years

Site	Male		Site	Female	
	No.	%		No.	%
Leukemia	92	42.4	Leukemia	45	35.2
Bone	45	20.7	Bone	30	23.4
Lymphoma	28	12.9	Brain	10	7.8
Brain	9	4.1	Lymphoma	10	7.8
Adrenal gland	8	3.7	Kidney	6	4.7

Leading site of cancer in the age group 20-34 years

Site	Male		Site	Female	
	No.	%		No.	%
Leukemia	70	20.0	Breast	80	22.6
Lymphoma	41	11.7	Leukemia	35	9.9
Rectum	24	6.9	Ovary	29	8.2
Mouth	23	6.6	Thyroid	29	8.2
Testis	20	5.7	Lymphoma	26	7.3

Leading site of cancer in the age group 35-64 years

Site	Male		Site	Female	
	No.	%		No.	%
Mouth	441	14.7	Breast	1306	33.7
Tongue	350	11.7	Cervix	587	15.1
Stomach	297	9.9	Ovary	267	6.9
Lung	205	6.8	Stomach	173	4.5
Rectum	140	4.7	Corpus uteri	155	4.0

Leading site of cancer in the age group 65+ years

Site	Male		Site	Female	
	No.	%		No.	%
Lung	132	10.8	Breast	216	23.8
Stomach	112	9.1	Cervix	109	12.0
Mouth	109	8.9	Mouth	75	8.3
Prostate	106	8.7	Ovary	45	5.0
Esophagus	76	6.2	Lung	44	4.8

Most valid basis of diagnosis

Method of diagnosis provides indicators towards the reliability of data. 89% of male and 90% of female cancers was microscopically confirmed. The distribution of number and proportion of cases by classified basis of diagnosis and site are given in Appendix 2a for males and Appendix 2b for females.

Table 9: Method of diagnosis by gender: 2021

Method of diagnosis	Male		Female		Total	
	No.	%	No.	%	No.	%
Clinical	81	1.7	78	1.5	159	1.6
Microscopic	4,254	88.9	4,844	91.9	9,098	90.5
X-ray/Imaging	450	9.4	345	6.5	795	7.9
Others	2	0.0	2	0.0	4	0.0
Total	4,787	100.0	5,269	100.0	10,056	100.0

Among 10,056 (90.5%) cases had microscopic confirmation. Among microscopically confirmed cases (88.7%) of cases were proved by primary histology.

Table 10: Microscopic verification of cancer cases by gender: 2021

Microscopic verification	Male		Female		Total	
	No.	%	No.	%	No.	%
Pri hist	3,638	85.5	4,429	91.4	8,067	88.7
Met hist	149	3.5	102	2.1	251	2.8
Bone Marrow	388	9.1	209	4.3	597	6.6
Blood film	1	0.0	0	0.0	1	0.0
Pri Cyto	38	0.9	80	1.7	118	1.3
Met Cyto	40	0.9	24	0.5	64	0.7
Total	4,254	100.0	4,844	100.0	9,098	100.0

Clinical extent of disease

The clinical extent of disease is the most viable surrogate for tumour stage. The distribution of cases by clinical extent of disease categorized as *localized*, *regional* (direct extension with or without involving regional nodes), *distant metastasis* and *unknown* (treated elsewhere/not applicable) by site is given in Appendix 3a for males and Appendix 3b for females. About 4.7% of cases had reported with a localized lesion for all cancers together among both sexes.

Table 11: Clinical extent of disease by gender: 2021

Extent of disease	Male		Female		Total	
	No.	%	No.	%	No.	%
Localised	213	4.4	257	4.9	470	4.7
Regional	2,126	44.4	2,640	50.1	4,766	47.4
Distant/Adv	806	16.8	851	16.2	1,657	16.5
Oth&Unk	1,642	34.3	1,521	28.9	3,163	31.5
Total	4,787	100.0	5,269	100.0	10,056	100.0

CANCER DIRECTED TREATMENT

With the majority of cases of all cancers together having a locally advanced disease (Males:44.4%; Females:50.1%) or a distant metastatic disease (Male:16.8%; Female:16.2%) at presentation, the scope of offering complete cure/long term survival is low and the choice of cases that can receive any radical cancer directed treatment becomes highly selective. The broad treatment groups by site is given in Appendix 4a for males and Appendix 4b for females. Cancer directed treatment was administered in 37.5% of the patients registered.

Table 12: Broad Treatment group by gender: 2021

Treatment status at RI	Male		Female		Total	
	No.	%	No.	%	No.	%
Prior Trt	914	19.1	1,000	19.0	1,914	19.0
Prior+RI	181	3.8	206	3.9	387	3.8
Only at RI	1,438	30.0	1,947	37.0	3,385	33.7
No TRT	2,254	47.1	2,116	40.2	4,370	43.5
Total	4,787	100.0	5,269	100.0	10,056	100.0

Table 13: Broad Treatment status by gender (excluding previously treated cases): 2021

Treatment status at RI	Male		Female		Total	
	No.	%	No.	%	No.	%
Received treatment	1,438	38.9	1,947	47.9	3,385	43.6
Not Received	2,122	57.5	1,967	48.4	4,089	52.7
Advised but accepted	14	0.4	11	0.3	25	0.3
Incomplete treatment	118	3.2	138	3.4	138	1.8
Total	3,692	100.0	4,063	100.0	7,755	99.9

The analytical cases for the HBCR are the cases where the diagnosis and treatment can be assessed for the patients treated so as to analyse the effectiveness of treatment. So excluding previously treated cases the broad treatment status by gender is given in Annexure 5a for male and Annexure 5b for female. 43.5% of patients had received atleast one form of cancer directed A history of having undergone any cancer directed treatment (surgery, radiotherapy, chemotherapy or hormone therapy) prior to reporting to the Cancer Institute (W.I.A) is present in 19.0% of cases for all cancers together. 37.5% of the patients were offered treatment at the institute. 43.5% of the patients did not receive any cancer directive treatment.

Table 14: Cancer directed treatment at the Cancer Institute (W.I.A)

Treatment administered	Male		Female		Total	
	No.	%	No.	%	No.	%
Surgery	163	11.3	146	7.5	309	9.1
Radiotherapy	114	7.9	103	5.3	217	6.4
Chemotherapy	354	24.6	312	16.0	666	19.7
Surgery+Radiotherapy	68	4.7	44	2.3	112	3.3
Surgery+Chemotherapy	111	7.7	214	11.0	325	9.6
Radiotherapy+Chemotherapy	434	30.2	358	18.4	792	23.4
Surg+Chemo+Radiotherapy	87	6.1	170	8.7	257	7.6
OTHERS	107	7.4	600	30.8	707	20.9
Total	1,438	100.0	1,947	100.0	3,385	100.0

Multimodality of treatment was offered to 64.8% of patients. Chemotherapy alone was administered in 19.7% of patients.


CHILDHOOD CANCERS (Appendix 7)

Predominance of boys was noticed among childhood cancer (Boys: 217; Girls: 128) with a sex ratio of 169 boys to 100 girls. Leukemia and Lymphoma constituted 50.7% of childhood cancers followed by bone tumors (21.4%). The order of cancers by histology type were Acute lymphoid leukemia (25.5%), Osteosarcoma (12.8%), Acute myeloid leukemia (8.7%), Ewing sarcoma (7.8%), Hodgkins lymphoma (7.0%), Chronic myeloproliferative disease (4.6%), Neuroblastoma (2.9%), Non-Hodgkins lymphoma (2.9%), Ependymomas (2.9%), Nephroblastoma (2.3%) of all childhood cancers.

CANCER TONGUE
2021 - ICD :C01-C02

Gender	#	% to total cancers
Male	430	9.0
Female	139	2.6
Total	569	5.6
M : F		0.3


Proportion (%) by agegroup



SUBSITE	#	%
Malignant neoplasm of bas	65	11.4
Dorsal surface of tongue	5	0.9
Border of tongue	415	72.9
Ventral surface of tongue	5	0.9
Anterior two-thirds of tong	13	2.3
Overlapping lesion of tong	20	3.5
Tongue, unspecified	46	8.1

HISTOLOGY TYPE	#	%
Carcinoma, NOS	8	1.5
Verrucous carcinoma, NOS	2	0.4
Squamous cell carcinoma, NOS	510	97.0
Squamous cell carcinoma, keratinizing, l	2	0.4
Squamous cell carcinoma, spindle cell	2	0.4
Adenoid cystic carcinoma	1	0.2
Fibrosarcoma, NOS	1	0.2
Histological Verification	526	92.4
No Histological Confirmation	43	7.6

STAGE OF DISEASE (%) - Treated cases




TREATMENT AT CI

Treatment	#	%
No/incomplete treatment	270	47.5
Previously treated cases	78	13.7
Treatment adv not accepted	0	0.0
Treated at CI	221	38.8
<u>Among treated cases at CI</u>		
Surgery	46	20.8
Radiotherapy	28	12.7
Chemotherapy	2	0.9
Sur+Radio	26	11.8
Radio+Chemo	115	52
Sur+Radio+Chemo	4	1.8

CASES TREATED IN 2017 -18 & FOLLOWED THROUGH 2022, ALL STAGES, (n=345)

Outcome of follow up	N	%
Alive	136	39.4
Dead	196	56.8
Lost to follow-up	13	3.8
<1yr	6	1.7
1-3 yrs	4	1.2
3-5 yrs	3	0.9
Complete follow up at 3 years:		97.1




CANCER MOUTH
2021 - ICD :C03-C06


Gender	#	% to total cancers
Male	572	11.9
Female	204	3.9
Total	776	7.7
M : F		0.4

SUBSITE	#	%
Upper gum	27	3.5
Lower gum	127	16.4
Gum, unspecified	7	0.9
Overlapping lesion of floor	1	0.1
Floor of mouth, unспеific	50	6.4
Hard palate	39	5.0
Soft palate	40	5.2
Uvula	2	0.3
Palate, unspecified	2	0.3
Cheek mucosa	435	56.1
Vestibule of mouth	5	0.6
Retromolar area	36	4.6
Mouth, unspecified	5	0.6

STAGE OF DISEASE (%) - Treated cases



Proportion (%) by agegroup



HISTOLOGY TYPE	#	%
Carcinoma, NOS	14	2
Pseudosarcomatous carcinoma	2	0.3
Verrucous carcinoma, NOS	9	1.3
Squamous cell carcinoma, NOS	639	93
Squamous cell carcinoma, keratinizing, l	5	0.7
Basaloid squamous cell carcinoma	2	0.3
Adenocarcinoma, NOS	2	0.3
Adenoid cystic carcinoma	3	0.4
Mucoepidermoid carcinoma	5	0.7
Others	6	0.6
Histological Verification	687	88.5
No Histological Confirmation	89	11.5

TREATMENT AT CI


	#	%
No/incomplete treatment	393	50.6
Previously treated cases	109	14.0
Treatment adv not accepted	0	0
Treated at CI	274	35.3

Among treated cases at CI

Surgery	39	14.2
Radiotherapy	41	15
Chemotherapy	2	0.7
Sur+Radio	42	15.3
Radio+Chemo	125	45.6
Sur+Radio+Chemo	25	9.1

CASES TREATED IN 2017 -18 & FOLLOWED THROUGH 2022, ALL STAGES, (n=445)


Outcome of follow up	N	%
Alive	132	29.7
Dead	293	65.8
Lost to follow-up	20	4.5
<1yr	6	1.4
1-3 yrs	6	1.4
3-5 yrs	8	1.8
Complete follow up at 3 years:		97.3



**CANCER HYPOPHARYNX
2021 - ICD :C12-C13**

Gender	#	% to total cancers
Male	163	3.4
Female	98	1.9
Total	261	2.6
M : F		0.6


Proportion (%) by agegroup



SUBSITE	#	%
Malig neo of piriform sinu	81	31.0
Postcricoid region	99	37.9
Aryepiglottic fold, hypoph	17	6.5
Posterior wall of hypophar	19	7.3
Overlapping lesion of hypc	9	3.4
Hypopharynx, unspecified	36	13.8

HISTOLOGY TYPE	#	%
Carcinoma, NOS	13	5.6
Squamous cell carcinoma, NOS	215	92.7
Squamous cell carcinoma, keratinizing, l	2	0.9
Adenocarcinoma, NOS	2	0.9
Histological Verification	232	88.9
No Histological Confirmation	29	11.1

STAGE OF DISEASE (%) - Treated cases




TREATMENT AT CI

	#	%
No/incomplete treatment	135	51.7
Previously treated cases	35	13.4
Treatment adv not accepted	0	0.0
Treated at CI	91	34.9
<u>Among treated cases at CI</u>		
Surgery	1	1.1
Radiotherapy	15	16.5
Chemotherapy	1	1.1
Sur+Radio	3	3.3
Radio+Chemo	69	75.8
Sur+Radio+Chemo	2	2.2

CASES TREATED IN 2017 -18 & FOLLOWED THROUGH 2022, ALL STAGES, (n=149)

Outcome of follow up	N	%
Alive	36	24.2
Dead	107	71.8
Lost to follow-up	6	4.0
<1yr	0	0.0
1-3 yrs	1	0.7
3-5 yrs	5	3.4
Complete follow up at 3 years:		99.3




**CANCER OESOPHAGUS
2021 - ICD :C15**

Gender	#	% to total cancers
Male	184	3.8
Female	94	1.8
Total	278	2.8
M : F		0.5

SUBSITE	#	%
Cervical part of oeso	7	2.5
Thoracic part of oeso	7	2.5
Upper third of oeso	28	10.1
Middle third of oeso	71	25.5
Lower third of oeso	88	31.7
Overlapping lesion of oeso	37	13.3
Oesophagus, unspecified	40	14.4


STAGE OF DISEASE (%) - Treated cases



CASES TREATED IN 2017 -18 & FOLLOWED THROUGH 2022, ALL STAGES, (n=148)

Outcome of follow up	N	%
Alive	38	25.7
Dead	87	58.8
Lost to follow-up	23	15.5
<1yr	7	4.7
1-3 yrs	11	7.4
3-5 yrs	5	3.4
Complete follow up at 3 years:		87.8


Proportion (%) by agegroup



HISTOLOGY TYPE	#	%
Carcinoma, NOS	10	3.8
Small cell carcinoma, NOS	1	0.4
Squamous cell carcinoma, NOS	223	84.5
Squamous cell carcinoma, keratinizing, l	3	1.1
Squamous cell carcinoma, large cell, nor	1	0.4
Adenocarcinoma, NOS	21	8.0
Neuroendocrine carcinoma, NOS	2	0.8
Signet ring cell carcinoma	2	0.8
Adenosquamous carcinoma	1	0.4
Histological Verification	264	95.0
No Histological Confirmation	14	5.0

TREATMENT AT CI

	#	%
No/incomplete treatment	182	65.5
Previously treated cases	28	10.1
Treatment adv not accepted	3	1.1
Treated at CI	65	23.4
<u>Among treated cases at CI</u>		
Radiotherapy	7	10.8
Chemotherapy	8	12.3
Radio+Chemo	39	60.0
Sur+Radio+Chemo	11	16.9




**CANCER STOMACH
2021 - ICD :C16**


Gender	#	% to total cancers
Male	428	8.9
Female	216	4.1
Total	644	6.4
M : F	.	0.5

SUBSITE	#	%
Cardia	113	17.5
Fundus of stomach	15	2.3
Body of stomach	71	11
Pyloric antrum	149	23.1
Pylorus	26	4
Lesser curvature of stomach	21	3.3
Greater curvature of stomach	4	0.6
Overlapping lesion of stomach	79	12.3
Stomach, unspecified	166	25.8

STAGE OF DISEASE (%) - Treated cases




Proportion (%) by agegroup



HISTOLOGY TYPE	#	%
Carcinoma, NOS	32	5.5
Squamous cell carcinoma, NOS	10	1.7
Adenocarcinoma, NOS	384	65.8
Carcinoma, diffuse type (C16.)	4	0.7
Carcinoid tumor, NOS	2	0.3
Neuroendocrine carcinoma, NOS	8	1.4
Papillary adenocarcinoma, NOS	3	0.5
Mucinous adenocarcinoma	4	0.7
Mucin-producing adenocarcinoma	8	1.4
Signet ring cell carcinoma	114	19.5
Gastrointestinal stromal sarcoma	10	1.7
Others	5	0.9
Histological Verification	584	90.7
No Histological Confirmation	60	9.3
TREATMENT AT CI	#	%
No/incomplete treatment	350	54.3
Previously treated cases	111	17.2
Treatment adv not accepted	7	1.1
Treated at CI	176	27.3
Among treated cases at CI	#	%
Surgery	5	2.8
Radiotherapy	2	1.1
Chemotherapy	96	54.5
Sur+Chemo	63	35.8
Radio+Chemo	7	4
Sur+Radio+Chemo	3	1.7

CASES TREATED IN 2017 -18 & FOLLOWED THROUGH 2022, ALL STAGES, (n=273)


Outcome of follow up	N	%
Alive	52	19.1
Dead	211	77.3
Lost to follow-up	10	3.7
<1yr	0	0.0
1-3 yrs	3	1.1
3-5 yrs	7	2.6
Complete follow up at 3 years:		98.9



CANCER COLON & RECTUM
2021 - ICD : C18 - C20

Gender	#	% to total cancers
Male	339	7.1
Female	205	3.9
Total	544	5.4
M : F		0.6


Proportion (%) by agegroup



SUBSITE	#	%
Caecum	24	4.4
Appendix	12	2.2
Ascending colon	54	9.9
Hepatic flexure	16	2.9
Transverse colon	14	2.6
Splenic flexure	5	0.9
Descending colon	14	2.6
Sigmoid colon	65	11.9
Overlap lesion of colon	6	1.1
Colon, unspecified	9	1.7
Rectosigmoid junction	51	9.4
Rectum	274	50.4

HISTOLOGY TYPE	#	%
Carcinoma, NOS	16	3.2
Adenocarcinoma, NOS	391	78.0
Neuroendocrine carcinoma, NOS	9	1.8
Papillary adenocarcinoma, NOS	2	0.4
Mucinous adenocarcinoma	39	7.8
Mucin-producing adenocarcinoma	5	1.0
Signet ring cell carcinoma	34	6.8
Others	5	1.0
Histological Verification	501	92.1
No Histological Confirmation	43	7.9

STAGE OF DISEASE (%) - Treated cases




TREATMENT AT CI	#	%
No/incomplete treatment	192	35.29
Previously treated cases	132	24.26
Treatment adv not accepted	2	0.4
Treated at CI	218	40.1

Among treated cases at CI	#	%
Surgery	26	11.9
Radiotherapy	7	3.2
Chemotherapy	51	23.4
Sur+Radio	1	0.5
Sur+Chemo	33	15.1
Radio+Chemo	50	22.9
Sur+Radio+Chemo	49	22.5
Hormone	1	0.5

CASES TREATED IN 2017 -18 & FOLLOWED THROUGH 2022, ALL STAGES, (n=330)


Outcome of follow up	N	%
Alive	168	50.9
Dead	149	45.2
Lost to follow-up	13	4.0
<1yr	2	0.6
1-3 yrs	2	0.6
3-5 yrs	9	2.7
Complete follow up at 3 years:		98.8



CANCER LARYNX
2021 - ICD : C32

Gender	#	% to total cancers
Male	146	3.0
Female	7	0.1
Total	153	1.5
M : F	.	.05


Proportion (%) by agegroup



SUBSITE	#	%
Glottis	79	51.6
Supraglottis	47	30.7
Subglottis	3	2
Laryngeal cartilage	1	0.7
Overlapping lesion of larynx	1	0.7
Larynx, unspecified	22	14.4

HISTOLOGY TYPE	#	%
Carcinoma, NOS	13	9.70
Squamous cell carcinoma, NOS	115	85.82
Others	6	4.48
Histological Verification	134	87.6
No Histological Confirmation	19	12.4

STAGE OF DISEASE (%) - Treated cases




TREATMENT AT CI

	#	%
No/incomplete treatment	67	43.8
Previously treated cases	30	19.6
Treatment adv not accepted	0	0.0
Treated at CI	56	36.6
<u>Among treated cases at CI</u>		
Surgery	8	14.3
Radiotherapy	19	33.9
Chemotherapy	1	1.8
Sur+Radio	9	16.1
Radio+Chemo	17	30.4
Sur+Radio+Chemo	2	3.6

CASES TREATED IN 2017 -18 & FOLLOWED THROUGH 2022, ALL STAGES, (n= 142)


Outcome of follow up	N	%
Alive	83	58.5
Dead	55	38.7
Lost to follow-up	4	2.8
<1yr	0	0.0
1-3 yrs	1	0.7
3-5 yrs	3	2.1
Complete follow up at 3 years:		99.3



**CANCER LUNG
2021 - ICD :C34**

Gender	#	% to total cancers
Male	346	7.2
Female	195	3.7
Total	541	5.4
M : F	.	0.6


Proportion (%) by agegroup



SUBSITE	#	%
Main bronchus	7	1.3
Upper lobe, bronchus or lu	221	40.9
Middle lobe, bronchus or l	21	3.9
Lower lobe, bronchus or lu	125	23.1
Overlapping lesion of bron	28	5.2
Bronchus or lung, unspecif	139	25.7

HISTOLOGY TYPE	#	%
Carcinoma, NOS	30	6.8
Small cell carcinoma, NOS	28	6.4
Non-small cell carcinoma (C34.)	23	5.3
Squamous cell carcinoma, NOS	57	13.0
Adenocarcinoma, NOS	261	59.6
Neuroendocrine carcinoma, NOS	7	1.6
Mucinous adenocarcinoma	7	1.6
Synovial sarcoma, NOS	3	0.7
Others	22	5.0
Histological Verification	438	81.0
No Histological Confirmation	103	19.0

STAGE OF DISEASE (%) - Treated cases




TREATMENT AT CI

	#	%
No/incomplete treatment	297	54.9
Previously treated cases	64	11.8
Treatment adv not accepted	1	0.2
Treated at CI	179	33.1
<u>Among treated cases at CI</u>		
Surgery	4	2.2
Radiotherapy	1	0.6
Chemotherapy	66	36.9
Sur+Chemo	4	2.2
Radio+Chemo	61	34.1
Sur+Radio+Chemo	1	0.6
Others	42	23.5

CASES TREATED IN 2017 -18 & FOLLOWED THROUGH 2022, ALL STAGES, (n=301)

Outcome of follow up	N	%
Alive	21	7.0
Dead	251	83.4
Lost to follow-up	29	9.6
<1yr	9	3.0
1-3 yrs	13	4.3
3-5 yrs	7	2.3
Complete follow up at 3 years:		92.7




**CANCER FEMALE BREAST
2021 - ICD :C50**

Gender	#	% to total cancers
Female	1604	30.4

SUBSITE	#	%
Nipple and areola	9	0.6
Central portion of breast	56	3.5
Upper-inner quadrant of b1	179	11.2
Lower-inner quadrant of b1	53	3.3
Upper-outer quadrant of b1	340	21.2
Lower-outer quadrant of b1	78	4.9
Axillary tail of breast	10	0.6
Overlapping lesion of brea	521	32.5
Breast, unspecified	358	22.3

STAGE OF DISEASE (%) - Treated cases




CASES TREATED IN 2017 -18 & FOLLOWED THROUGH 2022, ALL STAGES, (n= 1416)

Outcome of follow up	N	%
Alive	959	67.7
Dead	386	27.3
Lost to follow-up	71	5.0
<1yr	4	0.3
1-3 yrs	8	0.6
3-5 yrs	59	4.2
Complete follow up at 3 years:		99.2

Proportion (%) by agegroup

Median Age (F): 51 (19 - 90)




HISTOLOGY TYPE	#	%
Carcinoma, NOS	72	4.8
Adenocarcinoma, NOS	3	0.2
Papillary carcinoma, NOS	5	0.3
Mucinous adenocarcinoma	25	1.7
Infiltrating duct carcinoma, NOS (C50._	1345	89.7
Medullary carcinoma, NOS	2	0.1
Lobular carcinoma, NOS (C50._)	14	0.9
Metaplastic carcinoma, NOS	9	0.6
Phyllodes tumor, malignant (C50._)	8	0.5
Others	17	1.1
Histological Verification	1500	93.5
No Histological Confirmation	104	6.5

TREATMENT AT CI	#	%
No/incomplete treatment	515	32.1
Previously treated cases	308	19.2
Treatment adv not accepted	0	0.0
Treated at CI	781	48.7

Among treated cases at CI

Surgery	20	2.6
Chemotherapy	35	4.5
Sur+Chemo	41	5.2
Radio+Chemo	20	2.6
Sur+Radio+Chemo	105	13.4
Hormone	51	6.5
Sur+Hor	55	7.0
Chemo+Hor	38	4.9
Sur+Chemo+Hor	70	9.0
Radio+Chemo+Hor	23	2.9
Sur+Radio+Chemo+Hor	297	38.0
Others	26	3.4




**CANCER CERVIX
2021 - ICD :C53**

Gender	#	% to total cancers
Female	708	13.4

SUBSITE	#	%
Endocervix	11	1.6
Exocervix	1	0.1
Cervix uteri, unspecified	696	98.3

STAGE OF DISEASE (%) - Treated cases




CASES TREATED IN 2017 -18 & FOLLOWED THROUGH 2022, ALL STAGES, (n=712)

Outcome of follow up	N	%
Alive	450	63.2
Dead	242	34.0
Lost to follow-up	20	2.8
<1yr	5	0.7
1-3 yrs	5	0.7
3-5 yrs	10	1.4
Complete follow up at 3 years:		98.6

Proportion (%) by agegroup

Median Age (F): 53 (27 - 87)




HISTOLOGY TYPE	#	%
Carcinoma, NOS	41	6.0
Papillary squamous cell carcinoma	11	1.6
Squamous cell carcinoma, NOS	183	27.0
Squamous cell carcinoma, keratinizing, l	120	17.7
Squamous cell carcinoma, large cell, nor	245	36.1
Adenocarcinoma, NOS	48	7.1
Neuroendocrine carcinoma, NOS	3	0.4
Adenosquamous carcinoma	15	2.2
Others	13	1.9
Histological Verification	679	95.9
No Histological Confirmation	29	4.1

TREATMENT AT CI

	#	%
No/incomplete treatment	323	45.6
Previously treated cases	131	18.5
Treatment adv not accepted	0	0.0
Treated at CI	254	35.9

Among treated cases at CI

	#	%
Surgery	2	0.8
Radiotherapy	60	23.6
Chemotherapy	14	5.5
Sur+Radio	1	0.4
Radio+Chemo	164	64.6
Sur+Radio+Chemo	13	5.1




**CANCER VULVA,VAGINA & OTHERS
2021 - ICD :C51-52, C57**

Gender	#	% to total cancers
Female	72	1.4

SUBSITE	#	%
Vulva, unspecified	23	31.9
Malignant neoplasm of vag	47	65.3
Fallopian tube	1	1.4
Female genital organ, unsp	1	1.4

STAGE OF DISEASE (%) - Treated cases




CASES TREATED IN 2017 -18 & FOLLOWED THROUGH 2022, ALL STAGES, (n=39)

Outcome of follow up	N	%
Alive	17	43.6
Dead	13	33.3
Lost to follow-up	9	23.1
<1yr	2	5.1
1-3 yrs	7	18.0
3-5 yrs	0	0.0
Complete follow up at 3 years:		76.9

Proportion (%) by agegroup

Median Age (F): 62 (25 - 92)




HISTOLOGY TYPE	#	%
Carcinoma, NOS	6	8.8
Squamous cell carcinoma, NOS	43	63.2
Squamous cell carcinoma, keratinizing, l	3	4.4
Squamous cell carcinoma, large cell, nor	3	4.4
Adenocarcinoma, NOS	6	8.8
Malignant melanoma, NOS (except juve	2	2.9
Epithelioid sarcoma	2	2.9
Others	3	4.4
Histological Verification	68	94.4
No Histological Confirmation	4	5.6

TREATMENT AT CI

	#	%
No/incomplete treatment	36	50
Previously treated cases	11	15.3
Treatment adv not accepted	1	1.4
Treated at CI	24	33.3

Among treated cases at CI

	#	%
Surgery	3	12.5
Radiotherapy	11	45.8
Chemotherapy	2	8.3
Sur+Radio	1	4.2
Sur+Chemo	1	4.2
Radio+Chemo	5	20.8
Chemo+Hor	1	4.2




**CANCER CORPUS UTERI
2021 - ICD :C54**

Gender	#	% to total cancers
Female	203	3.9

SUBSITE	#	%
Endometrium	196	96.6
Myometrium	1	0.5
Corpus uteri, unspecified	6	3

STAGE OF DISEASE (%) - Treated cases




CASES TREATED IN 2017 -18 & FOLLOWED THROUGH 2022, ALL STAGES, (n=128)

Outcome of follow up	N	%
Alive	86	67.2
Dead	34	26.6
Lost to follow-up	8	6.3
<1yr	1	0.8
1-3 yrs	1	0.8
3-5 yrs	6	4.7
Complete follow up at 3 years:		98.4

Proportion (%) by agegroup


Median Age (F): 57 (27 - 81)



HISTOLOGY TYPE	#	%
Carcinoma, NOS	8	4.0
Adenocarcinoma, NOS	32	15.9
Clear cell adenocarcinoma, NOS	5	2.5
Endometrioid adenocarcinoma, NOS	115	57.2
Serous cystadenocarcinoma, NOS (C56)	11	5.5
Leiomyosarcoma, NOS	5	2.5
Endometrial stromal sarcoma, NOS (C54)	7	3.5
Endometrial stromal sarcoma, low grade	2	1.0
Carcinosarcoma, NOS	9	4.5
Others	7	3.5
Histological Verification	201	99.0
No Histological Confirmation	2	1.0

TREATMENT AT CI	#	%
No/incomplete treatment	49	24.1
Previously treated cases	56	27.6
Treatment adv not accepted	1	0.5
Treated at CI	97	47.8

Among treated cases at CI	#	%
Surgery	27	27.8
Radiotherapy	7	7.2
Chemotherapy	5	5.2
Sur+Radio	12	12.4
Sur+Chemo	16	16.5
Radio+Chemo	7	7.2
Sur+Radio+Chemo	13	13.4
Sur+Radio+Hor	5	5.2
Others	5	5.2




CANCER OVARY
2021 - ICD : C56

Gender	#	% to total cancers
Female	346	6.6

SUBSITE	#	%
Ovary	346	100.0
Histological Verification	310	89.6
No Histl Confirmation	36	10.4

STAGE OF DISEASE (%) - Treated cases




CASES TREATED IN 2017 -18 & FOLLOWED THROUGH 2022, ALL STAGES, (n=244)

Outcome of follow up	N	%
Alive	112	45.9
Dead	113	46.3
Lost to follow-up	19	7.8
<1yr	2	0.8
1-3 yrs	12	4.9
3-5 yrs	5	2.1
Complete follow up at 3 years:		94.3

Proportion (%) by agegroup

Median Age (F): 51(1 - 86)




HISTOLOGY TYPE	#	%
Carcinoma, NOS	40	12.9
Adenocarcinoma, NOS	54	17.4
Clear cell adenocarcinoma, NOS	6	1.9
Endometrioid adenocarcinoma, NOS	5	1.6
Serous cystadenocarcinoma, NOS (C56.1)	139	44.8
Papillary serous cystadenocarcinoma (C56.2)	8	2.6
Mucinous adenocarcinoma	13	4.2
Granulosa cell tumor, malignant (C56.9)	10	3.2
Mixed germ cell tumor	5	1.6
Others	30	9.7

TREATMENT AT CI

	#	%
No/incomplete treatment	109	31.5
Previously treated cases	80	23.1
Treatment adv not accepted	1	0.3
Treated at CI	156	45.1

Among treated cases at CI

	#	%
Surgery	9	5.8
Chemotherapy	43	27.6
Sur+Chemo	100	64.1
Radio+Hor	1	0.6
Chemo+Hor	2	1.3
Sur+Chemo+Hor	1	0.6




CANCER PENIS
2021 - ICD : C60, C63

Gender	#	% to total cancers
Male	71	1.5

SUBSITE	#	%
Prepuce	4	5.6
Glans penis	20	28.2
Overlapping lesion of peni	7	9.9
Penis, unspecified	40	56.3

STAGE OF DISEASE (%) - Treated cases




CASES TREATED IN 2017 -18 & FOLLOWED THROUGH 2022, ALL STAGES, (n=52)

Outcome of follow up	N	%
Alive	20	38.5
Dead	19	36.5
Lost to follow-up	13	25.0
<1yr	0	0.0
1-3 yrs	6	11.5
3-5 yrs	7	13.5
Complete follow up at 3 years:		88.5

Proportion (%) by agegroup

Median Age (M): 55 (35 - 80)




HISTOLOGY TYPE	#	%
Carcinoma, NOS	2	2.9
Verrucous carcinoma, NOS	3	4.3
Squamous cell carcinoma, NOS	60	85.7
Squamous cell carcinoma, keratinizing, l	2	2.9
Squamous cell carcinoma, spindle cell	1	1.4
Basaloid squamous cell carcinoma	1	1.4
Basal cell carcinoma, NOS (C44. .)	1	1.4
Histological Verification	70	98.6
No Histological Confirmation	1	1.4

TREATMENT AT CI

	#	%
No/incomplete treatment	17	23.9
Previously treated cases	18	25.4
Treatment adv not accepted	0	0.0
Treated at CI	36	50.7
<u>Among treated cases at CI</u>		
Surgery	24	66.7
Chemotherapy	5	13.9
Sur+Chemo	5	13.9
Radio+Chemo	1	2.8
Radio+Hor	1	2.8

OVER ALL SURVIVAL (%)




CANCER LYMPHOMA
2021 - ICD : C81-85, C96


Gender	#	% to total cancers
Male	226	4.7
Female	136	2.6
Total	362	3.6
M : F	.	0.6

HISTOLOGY TYPE	#	%
<u>Hodgkin's Lymphoma</u>		
Nodular Hodgkin's lymphc	24	6.6
Mixed cellular	29	8.0
NOS	45	12.4
<u>Non Hodgkin's Lymphoma</u>		
Follicular Lymphoma	22	6.1
Large B-cell	57	15.7
Diffuse Lymphoblastic	6	1.7
Burkitt	3	0.8
Non follicular	22	6.1
T cell	24	6.6
Lymphosarcoma	56	15.5
Oth and Uns lymph, haema related tissue	45	12.4
	29	8.0

STAGE OF DISEASE (%) - Treated cases



Proportion (%) by agegroup




SITE	#	%
<u>Nodal</u>		
Cervical	58	16.0
Abdominal	9	2.5
Axillary	12	3.3
Inguinal	17	4.7
Multiple/Others	120	33.1
<u>Extranodal</u>		
Tonsil	4	1.1
Stomach	10	2.8
Colo-Rectum	3	0.8
Liver	6	1.7
Lung	6	1.7
Mediastinum	12	3.3
Bone	4	1.1
Bone marrow	60	16.6
Eye	3	0.8
Brain	5	1.4
Others	33	9.1

TREATMENT AT CI	#	%
No/incomplete treatment	126	34.8
Previously treated cases	73	20.2
Treatment adv not accepted	1	0.3
Treated at CI	162	44.8

Among treated cases at CI	#	%
Radiotherapy	3	1.9
Chemotherapy	126	77.8
Radio+Chemo	31	19.1
Others	2	1.2

CASES TREATED IN 2017 -18 & FOLLOWED THROUGH 2022, ALL STAGES, (n=357)

Outcome of follow up	N	%
Alive	234	65.6
Dead	103	28.9
Lost to follow-up	20	5.6
<1yr	1	0.3
1-3 yrs	9	2.5
3-5 yrs	10	2.8
Complete follow up at 3 years:		97.2




CANCER LEUKEMIA
2021 - ICD : C91-95

Gender	#	% to total cancers
Male	302	6.3
Female	165	3.1
Total	467	4.6
M : F	.	0.5

HISTOLOGY TYPE	#	%
<u>Lymphoid Leukemia</u>		
Acute	148	22.4
Chronic	30	4.5
<u>Myeloid Leukemia</u>		
Acute	108	16.3
Chronic	74	11.2
Acute promyelocytic	6	0.9
Other myeloid	73	11.0
<u>Leukemia NOS</u>		
Acute	8	1.2
Others	20	3.0


Proportion (%) by agegroup



TREATMENT AT CI	#	%
No/incomplete treatment	179	38.3
Previously treated cases	84	18.0
Treatment adv not accepted	0	0.0
Treated at CI	204	43.7
<u>Among treated cases at CI</u>		
Chemotherapy	183	89.7
Radio+Chemo	19	9.3
Others	2	1.0

CASES TREATED IN 2017 -18 & FOLLOWED THROUGH 2022, ALL STAGES, (n=495)


Outcome of follow up	N	%
Alive	305	61.6
Dead	167	33.7
Lost to follow-up	23	4.7
<1yr	8	1.6
1-3 yrs	3	0.6
3-5 yrs	12	2.4
Complete follow up at 3 years:		97.8



CANCER - CHILDHOOD 0-19 YEARS
2021 - ALL SITES

Gender	#	% to total cancers
Male	217	4.5
Female	128	2.4
Total	345	3.4
M : F	.	0.6

Proportion (%) by agegroup




TREATMENT AT CI	#	%
No/incomplete trt	65	18.8
Previously trt cases	77	22.3
Trt adv not accepted	2	0.6
Treated at CI	201	58.3

Among treated cases at CI

Chemotherapy	118	58.6
Sur+Chemo	45	22.4
Radio+Chemo	19	9.5
Others	19	9.5

CASES TREATED IN 2017-18 & FOLLOWED THROUGH 2022, ALL STAGES, (n=455)

Outcome of follow up	N	%
Alive	256	56.3
Dead	134	29.5
Lost to follow-up	65	14.3
<1yr	12	2.6
1-3 yrs	25	5.5
3-5 yrs	28	6.2
Complete follow up at 3 years:		91.9




Cancer Pattern	No	%
<u>I Leukemias, myeloproliferative diseases</u>	137	39.7
1(a) Lymphoid leukemias	88	25.5
1(b) Acute myeloid leukemias	30	8.7
1(c) Chronic myeloproliferative diseases	16	4.6
1(e) Unspecified and other specified leukemias	3	0.9
<u>II Lymphomas and reticuloendothelial neoplasms</u>	38	11.0
2(a) Hodgkin lymphomas	24	7.0
2(b) Non-Hodgkin lymphomas	10	2.9
2(c) Burkitt lymphoma	2	0.6
2(d) Miscellaneous lymphoreticular neoplasms	1	0.3
2(e) Unspecified lymphomas	1	0.3
<u>III CNS & misc intracranial & intraspinal neoplasms</u>	17	4.9
3(a) Ependymomas and choroid plexus tumor	10	2.9
3(b) Astrocytomas	4	1.2
3(c) Intracranial and intraspinal embryonal tumors	1	0.3
3(d) Other gliomas	2	0.6
<u>IV Neuroblastoma & oth peripheral nervous cell tum</u>	10	2.9
4(a) Neuroblastoma and ganglioneuroblastoma	10	2.9
<u>V Retinoblastoma</u>	4	1.2
<u>VI Renal tumors</u>	11	3.2
6(a) Nephroblastoma & oth nonepithelial renal tum	8	2.3
6(b) Renal carcinomas	1	0.3
6(c) Unspecified malignant renal tumors	2	0.6
<u>VII Hepatic tumors</u>	5	1.4
7(a) Hepatoblastoma	4	1.2
7(b) Hepatic carcinomas	1	0.3
<u>VIII Malignant bone tumors</u>	74	21.4
8(a) Osteosarcomas	44	12.8
8(b) Chondrosarcomas	2	0.6
8(c) Ewing tumor and related sarcomas of bone	27	7.8
8(d) Other specified malignant bone tumors	1	0.3
<u>IX Soft tissue and other extraosseous sarcomas</u>	22	6.4
<u>9(a) Rhabdomyosarcomas</u>	7	2.0
9(b) Fibrosarcomas, peripheral nerve sheath tumors neo	2	0.6
9(d) Other specified soft tissue sarcomas	7	2.0
9(e) Unspecified soft tissue sarcomas	6	1.7
<u>X Germ cell tumors, trophoblastic tumors</u>	11	3.2
<u>10(a) Intracranial and intraspinal germ cell tumors</u>	1	0.3
10(b) Malignant extracranial and extragonadal GCT	4	1.2
10(c) Malignant gonadal germ cell tumors	5	1.4
10(e) Other and unspecified malignant gonadal tumors	1	0.3
<u>XI Oth malig epithelial neoplasms & malig melanomas</u>	13	3.8
<u>11(b) Thyroid carcinomas</u>	3	0.9
11(c) Nasopharyngeal carcinomas	1	0.3
11(f) Other and unspecified carcinomas	9	2.6
<u>XII Other and unspecified malignant neoplasms</u>	3	0.9
<u>12(b) Other unspecified malignant tumors</u>	3	0.9
Total	345	100.0

**TOBACCO RELATED CANCERS
2021**

Gender	#	% to total cancers
Male	2003	41.8
Female	790	15.0
Total	2793	27.8
M : F	.	0.4


Proportion (%) by agegroup



SUBSITE	#	%
Lip	38	1.4
Tongue	569	20.3
Mouth	776	27.7
Pharynx	320	11.4
Oesophagus	278	9.9
Larynx	153	5.5
Lung	542	19.4
Urinary Bladder	117	4.2

HISTOLOGY TYPE	#	%
Carcinoma, NOS	99	4.0
Small cell carcinoma, NOS	30	1.2
Non-small cell carcinoma (C34. _)	23	0.9
Verrucous carcinoma, NOS	14	0.6
Squamous cell carcinoma, NOS	1836	74.2
Squamous cell carcinoma, keratinizing, l	12	0.5
Transitional cell carcinoma	52	2.1
Papillary transitional cell carcinoma (C6	42	1.7
Adenocarcinoma, NOS	289	11.7
Others	77	3.1
Histological Verification	2474	88.6
No Histological Confirmation	319	11.4

STAGE OF DISEASE (%) - Treated cases



TREATMENT AT CI	#	%
No/incomplete treatment	1423	50.9
Previously treated cases	412	14.8
Treatment adv not accepted	5	0.2
Treated at CI	953	34.1
<u>Among treated cases at CI</u>		
Surgery	120	12.6
Radiotherapy	117	12.3
Chemotherapy	82	8.6
Sur+Radio	81	8.5
Sur+Chemo	29	3.0
Radio+Chemo	432	45.3
Sur+Radio+Chemo	50	5.2
Others	42	4.5

LIST OF APPENDICES

Appendix 1 a & 1 b	Number of Cancers by Site (ICD-10) and 5 year Age Group: 2021 – Male & Female
Appendix 2 a & 2 b	Number (#) and Proportion(%) of Cancers by site (ICD 10) and method of Diagnosis: 2021 – Male & Female
Appendix 3 a & 3 b	Number (#) and Proportion (%) of cancers by site ICD 10 and clinical extent of disease: 2021 – Male & Female
Appendix 4 a & 4 b	Number (#) and Proportion (%) of cancers by site ICD10 and broad treatment group: 2021 – Male & Female
Appendix 5 a & 5 b	Number (#) and proportion (%) of cancers by site ICD 10 and treatment status at reporting institution (excluding the cancers previously treated): 2021 – Male & Female
Appendix 6 a & 6 b	Number (#) and Proportion (%) of cancer by site (ICD 10) and type of treatments at Reporting Institution (Excluding the cancers previously treated): 2021 – Male & Female
Appendix 7 a & 7 b	Number (#) and Proportion (%) of cancer by site (ICD 10) and any specific treatment at Reporting Institution (Excluding the cancers previously treated): 2021 – Male & Female
Appendix 8	Classification of Childhood Cancers (aged 0-19 years) : 2021

Appendix :1(a) : Number of Cancers by Site (ICD-10) and 5 year Age Group: 2021 – Male

ICD-10	SITE	00-	05-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75+	Total	%
C00	LIP	0	0	0	0	0	0	1	2	3	2	5	5	1	2	0	2	23	0.5
C01-02	TONGUE	0	0	0	0	1	2	12	31	51	62	78	61	67	33	18	14	430	9.0
C03-06	MOUTH	0	0	0	1	0	6	17	49	72	102	77	77	62	45	46	18	572	11.9
C07-08	SALIVARY GL	0	0	0	0	2	0	1	0	2	1	3	2	2	2	3	1	19	0.4
C09	TONSIL	0	0	0	0	1	1	2	2	2	7	6	11	12	8	3	5	60	1.3
C10	OTHER ORPHX	0	0	0	0	0	0	0	1	1	2	7	10	14	5	5	3	48	1.0
C11	NASOPHARYNX	0	0	0	1	3	3	1	1	1	4	3	7	4	5	3	0	36	0.8
C12-13	HYPOPHARYNX	0	0	0	0	1	1	5	2	9	12	20	32	26	23	22	10	163	3.4
C14	PHARYNX	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	2	0.0
C15	OESOPHAGUS	0	0	0	0	0	0	1	4	2	18	22	30	31	30	23	23	184	3.8
C16	STOMACH	0	0	0	0	1	6	12	16	25	47	67	79	63	63	28	21	428	8.9
C17	SMALL INTEST	0	0	0	1	0	1	0	5	0	3	0	3	1	0	2	1	17	0.4
C18	COLON	0	0	0	1	1	7	6	3	15	18	16	16	12	15	15	7	132	2.8
C19-20	RECTUM	0	0	0	1	1	13	10	16	17	16	33	32	26	18	6	18	207	4.3
C21	ANUS	0	0	0	0	0	0	0	3	0	4	5	2	2	1	2	0	19	0.4
C22	LIVER	2	0	0	1	2	0	2	2	13	16	24	32	38	27	21	16	196	4.1
C23-24	GALLBLAD ETC	0	0	0	0	0	1	3	5	8	9	9	9	18	8	6	7	83	1.7
C25	PANCREAS	0	0	0	0	0	0	0	6	8	10	11	14	11	13	4	6	83	1.7
C30-31	NOSE SINUS ETC	1	0	0	0	1	1	3	0	1	3	4	1	2	4	4	2	27	0.6
C32	LARYNX	0	1	0	1	0	0	0	3	7	10	13	28	28	24	14	17	146	3.0
C33-34	TRAC BRONC LUNG	0	0	0	0	2	2	5	9	10	20	37	60	69	62	44	26	346	7.2
C37-38	OT THORACIC ORG	0	0	0	1	5	4	0	1	0	0	4	2	1	1	1	0	20	0.4
C40-41	BONE	7	4	16	18	11	4	2	6	3	4	4	1	2	0	1	1	84	1.8
C43	MELANOMA SKIN	0	0	0	0	0	0	0	0	3	1	6	3	3	2	2	1	21	0.4
C44	OTHER SKIN	0	1	0	0	1	0	2	3	4	6	7	6	9	3	6	6	54	1.1
C45	MESOTHELIOMA	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	0.0
C47+49	CON & SOFT TISS	2	0	2	4	4	7	6	5	8	2	5	8	5	7	2	2	69	1.4
C50	BREAST	0	0	0	0	0	0	0	1	0	0	1	2	3	1	2	0	10	0.2
C60	PENIS	0	0	0	0	0	0	0	5	3	11	14	11	13	8	3	3	71	1.5
C61	PROSTATE	0	0	0	0	0	0	0	0	0	2	6	20	23	33	40	33	157	3.3
C62	TESTIS	0	0	0	1	4	13	3	6	2	0	2	2	0	0	0	0	33	0.7
C64	KIDNEY	5	0	0	1	0	1	2	6	10	12	12	15	13	10	6	1	94	2.0
C66	URETER	0	0	0	0	0	0	0	0	0	0	0	0	1	2	0	0	3	0.1
C67	URINARY BLADDER	0	0	1	0	0	2	0	3	2	7	9	11	15	19	8	12	89	1.9
C68	OTHER URINARY O	0	0	0	0	0	0	0	1	0	0	0	1	0	0	1	0	3	0.1
C69	EYE	2	1	0	0	0	0	0	0	1	0	0	0	1	0	0	0	5	0.1
C70-72	BRAIN NERVOUS S	4	3	1	1	3	5	6	2	6	8	5	6	7	5	1	1	64	1.3
C73	THYROID	0	0	1	1	3	3	2	4	5	8	6	5	12	5	4	0	59	1.2
C74-75	ADRL & OT ENDO	5	3	0	0	0	0	0	0	0	0	0	1	0	2	0	1	12	0.3
C77	SEC LYMPH NODE	0	0	0	0	0	0	2	0	4	5	9	6	15	12	8	2	63	1.3
C78	SEC RESP & DIGE	0	0	0	0	0	1	0	0	2	3	2	7	3	3	5	1	27	0.6
C79	SEC OTHERS	0	0	0	0	0	0	0	1	0	1	6	4	5	1	1	0	19	0.4
C81	HODGKIN DISEASE	0	5	6	8	8	4	6	3	7	7	1	4	4	5	0	1	69	1.4
C82-85,96	NHL	0	4	2	3	6	10	7	9	9	9	15	28	15	18	13	9	157	3.3
C90	MULTIPLE MYELOM	0	0	0	0	1	0	1	4	3	6	10	6	13	10	6	5	65	1.4
C91	LYMPHOID LEUK	25	11	6	14	13	5	10	5	6	2	3	4	4	7	4	1	120	2.5
C92-94	MYELOID LEU	5	4	7	20	7	14	21	22	15	13	5	12	14	10	2	3	174	3.6
C95	LEU UNSPECIFIED	0	0	0	0	0	0	0	0	0	4	2	0	1	0	0	1	8	0.2
O&U	OT & UNCERTAIN	0	0	0	1	0	0	0	1	1	1	3	2	1	2	2	1	15	0.3
C00-C96	ALL SITES	58	37	42	80	82	117	151	248	341	478	577	679	672	555	388	282	4787	100.0

Appendix : 1(b) : Number of Cancers by Site (ICD-10) and 5 year Age Group: 2021 - Female

ICD 10	SITE	00-	05-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75+	TOTAL	%
C00	LIP	0	0	0	0	0	0	0	0	0	2	4	2	4	2	1	0	15	0.3
C01-02	TONGUE	0	0	0	0	1	0	4	5	17	20	36	18	16	12	8	2	139	2.6
C03-06	MOUTH	0	0	0	0	0	0	3	2	12	16	34	30	32	32	20	23	204	3.9
C07-08	SALIVARY GL	0	0	0	0	0	0	3	1	4	2	3	1	0	1	2	0	17	0.3
C09	TONSIL	0	0	0	0	0	0	1	0	0	0	1	1	2	1	0	0	6	0.1
C10	OTHER ORPHX	0	0	0	0	0	0	0	1	0	0	2	2	1	0	1	1	8	0.2
C11	NASOPHARYNX	0	0	0	0	6	0	0	0	1	0	1	2	2	3	0	0	15	0.3
C12-13	HYPOPHARYNX	0	0	0	0	0	2	6	9	12	13	19	9	14	8	5	1	98	1.9
C14	PHARYNX	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0.0
C15	OESOPHAGUS	0	0	0	0	0	0	0	2	11	9	17	23	9	10	5	8	94	1.8
C16	STOMACH	0	0	0	1	4	5	6	22	17	28	38	39	29	11	10	6	216	4.1
C17	SMALL INTEST	0	0	0	0	0	0	0	1	0	2	1	3	2	0	0	0	9	0.2
C18	COLON	0	0	0	0	0	2	0	8	5	19	9	14	12	7	7	4	87	1.7
C19-20	RECTUM	0	0	0	0	2	3	4	6	4	18	16	15	19	11	11	9	118	2.2
C21	ANUS	0	0	0	0	0	0	0	0	1	1	3	4	5	3	3	2	22	0.4
C22	LIVER	1	1	0	0	2	0	3	3	6	6	12	10	9	7	4	3	67	1.3
C23-24	GALLBLAD ETC	0	0	0	0	0	1	5	4	6	12	10	11	7	8	3	0	67	1.3
C25	PANCREAS	0	0	0	0	0	1	4	2	5	5	11	7	7	9	6	5	62	1.2
C30-31	NOSE SINUS ETC	0	0	0	0	1	1	3	0	2	5	2	3	4	0	1	0	22	0.4
C32	LARYNX	0	0	0	0	0	1	0	0	0	1	1	1	1	1	0	1	7	0.1
C33-34	TRAC BRONC LUNG	0	0	0	2	0	1	3	10	18	26	34	33	25	25	13	6	196	3.7
C37-38	OT THORACIC ORG	0	0	0	0	2	1	0	1	1	0	1	0	0	0	0	0	6	0.1
C40-41	BONE	4	6	9	11	8	4	0	2	2	0	2	1	1	1	1	1	53	1.0
C43	MELANOMA SKIN	0	0	0	0	0	0	0	4	1	0	3	4	5	1	1	2	21	0.4
C44	OTHER SKIN	0	0	1	0	0	2	3	1	4	2	5	4	3	2	5	2	34	0.6
C47+49	CON & SOFT TISS	3	0	1	1	3	3	3	2	8	5	5	6	2	1	2	2	47	0.9
C50	BREAST	0	0	0	2	2	23	55	132	210	284	245	267	168	108	64	44	1604	30.4
C51	VULVA	0	0	0	0	0	1	0	0	1	0	3	1	5	4	6	2	23	0.4
C52	VAGINA	0	0	0	0	0	0	0	0	5	5	4	3	7	8	5	10	47	0.9
C53	CERVIX UTERI	0	0	0	0	0	3	9	32	78	118	136	130	93	63	28	18	708	13.4
C54	CORPUS UTERI	0	0	0	0	0	2	5	9	8	23	35	43	37	24	11	6	203	3.9
C55	UTERUS UNSPECIF	0	0	0	0	0	1	0	0	3	1	1	1	0	0	1	0	8	0.2
C56	OVARY	1	0	0	4	10	8	11	22	36	60	50	49	50	24	14	7	346	6.6
C57	OT FEMALE GENIT	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0	2	0.0
C58	PLACENTA	0	0	0	1	1	5	0	0	1	0	0	0	0	0	0	0	8	0.2
C64	KIDNEY	3	2	0	1	1	2	1	5	2	3	4	12	5	8	2	1	52	1.0
C66	URETER	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0.0
C67	URINARY BLADDER	0	0	0	0	0	0	0	1	0	2	2	4	6	6	5	2	28	0.5
C68	OTHER URINARY O	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	2	0.0
C69	EYE	2	0	0	0	0	0	0	1	0	0	1	0	0	0	1	0	5	0.1
C70-72	BRAIN NERVOUS S	2	4	2	2	1	6	4	3	3	3	3	1	2	1	1	0	38	0.7
C73	THYROID	0	0	0	1	9	11	9	23	13	19	12	10	11	7	5	3	133	2.5
C74-75	ADRL & OT ENDO	1	1	1	0	0	0	0	0	1	0	0	1	0	0	0	0	5	0.1
C77	SEC LYMPH NODE	0	0	0	0	0	0	0	2	0	6	6	4	5	3	4	1	31	0.6
C78	SEC RESP & DIGE	0	0	0	0	0	0	1	1	0	2	2	3	2	7	1	3	22	0.4
C79	SEC OTHERS	0	0	0	0	0	0	0	0	1	6	2	4	1	2	2	0	18	0.3
C81	HODGKIN DISEASE	0	2	1	2	6	8	2	1	1	1	1	1	0	1	1	1	29	0.6
C82-85,96	NHL	0	1	2	2	2	2	6	10	10	11	13	13	9	13	10	3	107	2.0
C90	MULTIPLE MYELOM	0	0	0	0	0	0	1	2	1	5	3	6	9	3	2	1	33	0.6
C91	LYMPHOID LEUK	13	7	5	7	2	4	2	0	2	4	3	5	3	3	2	1	63	1.2
C92-94	MYELOID LEU	2	0	3	8	6	10	11	7	14	7	9	10	5	3	1	2	98	1.9
C95	LEU UNSPECIFIED	0	0	0	0	0	0	0	0	0	1	1	0	1	0	0	1	4	0.1
O&U	OT & UNCERTAIN	1	0	1	0	0	1	3	1	4	0	3	1	2	1	2	0	20	0.4
C00-C96	ALL SITES	33	24	26	45	69	114	171	339	531	755	809	813	632	446	278	184	5269	100.0

Appendix: 2(a) Number (#) and Proportion(%) of Cancers by site (ICD 10) and method of Diagnosis: 2021 - Male

ICD 10	SITE	METHOD OF DIAGNOSIS									
		CLINICAL		MICROSCOPIC		IMAGING		OTHERS*		TOTAL	
		#	%	#	%	#	%	#	%	#	%
C00	LIP	1	4.3	22	95.7	0	0.0	0	0.0	23	100
C01-02	TONGUE	18	4.2	396	92.1	16	3.7	0	0.0	430	100
C03-06	MOUTH	41	7.2	515	90.0	16	2.8	0	0.0	572	100
C07-08	SALIVARY GL	0	0.0	18	94.7	1	5.3	0	0.0	19	100
C09	TONSIL	5	8.3	51	85.0	4	6.7	0	0.0	60	100
C10	OTHER ORPHX	3	6.2	40	83.3	5	10.4	0	0.0	48	100
C11	NASOPHARYNX	0	0.0	35	97.2	1	2.8	0	0.0	36	100
C12-13	HYPOPHARYNX	3	1.8	138	84.7	22	13.5	0	0.0	163	100
C14	PHARYNX	0	0.0	2	100.0	0	0.0	0	0.0	2	100
C15	OESOPHAGUS	0	0.0	172	93.5	11	6.0	1	0.5	184	100
C16	STOMACH	0	0.0	384	89.7	44	10.3	0	0.0	428	100
C17	SMALL INTEST	0	0.0	16	94.1	1	5.9	0	0.0	17	100
C18	COLON	0	0.0	122	92.4	10	7.6	0	0.0	132	100
C19-20	RECTUM	0	0.0	195	94.2	12	5.8	0	0.0	207	100
C21	ANUS	0	0.0	19	100.0	0	0.0	0	0.0	19	100
C22	LIVER	0	0.0	112	57.1	84	42.9	0	0.0	196	100
C23-24	GALLBLAD ETC	0	0.0	48	57.8	35	42.2	0	0.0	83	100
C25	PANCREAS	0	0.0	45	54.2	38	45.8	0	0.0	83	100
C30-31	NOSE SINUS ETC	1	3.7	25	92.6	1	3.7	0	0.0	27	100
C32	LARYNX	2	1.4	127	87.0	16	11.0	1	0.7	146	100
C33-34	TRAC BRONC LUNG	1	0.3	278	80.3	67	19.4	0	0.0	346	100
C37-38	OT THORACIC ORG	0	0.0	20	100.0	0	0.0	0	0.0	20	100
C40-41	BONE	0	0.0	82	97.6	2	2.4	0	0.0	84	100
C43	MELANOMA SKIN	0	0.0	21	100.0	0	0.0	0	0.0	21	100
C44	OTHER SKIN	0	0.0	54	100.0	0	0.0	0	0.0	54	100
C45	MESOTHELIOMA	0	0.0	1	100.0	0	0.0	0	0.0	1	100
C47+49	CON & SOFT TISS	0	0.0	69	100.0	0	0.0	0	0.0	69	100
C50	BREAST	0	0.0	10	100.0	0	0.0	0	0.0	10	100
C60	PENIS	0	0.0	70	98.6	1	1.4	0	0.0	71	100
C61	PROSTATE	0	0.0	152	96.8	5	3.2	0	0.0	157	100
C62	TESTIS	1	3.0	30	90.9	2	6.1	0	0.0	33	100
C64	KIDNEY	0	0.0	78	83.0	16	17.0	0	0.0	94	100
C66	URETER	0	0.0	3	100.0	0	0.0	0	0.0	3	100
C67	URINARY BLADDER	0	0.0	81	91.0	8	9.0	0	0.0	89	100
C68	OTHER URINARY O	0	0.0	3	100.0	0	0.0	0	0.0	3	100
C69	EYE	0	0.0	5	100.0	0	0.0	0	0.0	5	100
C70-72	BRAIN NERVOUS S	0	0.0	59	92.2	5	7.8	0	0.0	64	100
C73	THYROID	0	0.0	59	100.0	0	0.0	0	0.0	59	100
C74-75	ADRL & OT ENDO	0	0.0	11	91.7	1	8.3	0	0.0	12	100
C77	SEC LYMPH NODE	5	7.9	57	90.5	1	1.6	0	0.0	63	100
C78	SEC RESP & DIGE	0	0.0	16	59.3	11	40.7	0	0.0	27	100
C79	SEC OTHERS	0	0.0	7	36.8	12	63.2	0	0.0	19	100
C81	HODGKIN DISEASE	0	0.0	69	100.0	0	0.0	0	0.0	69	100
C82-85,96	NHL	0	0.0	157	100.0	0	0.0	0	0.0	157	100
C90	MULTIPLE MYELOM	0	0.0	65	100.0	0	0.0	0	0.0	65	100
C91	LYMPHOID LEUK	0	0.0	120	100.0	0	0.0	0	0.0	120	100
C92-94	MYELOID LEU	0	0.0	174	100.0	0	0.0	0	0.0	174	100
C95	LEU UNSPECIFIED	0	0.0	8	100.0	0	0.0	0	0.0	8	100
O&U	OT & UNCERTAIN	0	0.0	13	86.7	2	13.3	0	0.0	15	100
C00-C96	ALL SITES	81	1.7	4254	88.9	450	9.4	2	0.0	4787	100

* Others comprises endoscopy, exploratory surgery and isotopes

Appendix: 2(b) Number (#) and Proportion(%) of Cancers by site (ICD 10) and method of Diagnosis: 2021 - Female

ICD	SITE	METHOD OF DIAGNOSIS									
		CLINICAL		MICROSCOPIC		IMAGING		OTHERS*		TOTAL	
		#	%	#	%	#	%	#	%	#	%
C00	LIP	0	0.0	15	100.0	0	0.0	0	0.0	15	100
C01-02	TONGUE	7	5.0	130	93.5	2	1.4	0	0.0	139	100
C03-06	MOUTH	26	12.7	172	84.3	6	2.9	0	0.0	204	100
C07-08	SALIVARY GL	0	0.0	17	100.0	0	0.0	0	0.0	17	100
C09	TONSIL	0	0.0	4	66.7	2	33.3	0	0.0	6	100
C10	OTHER ORPHX	0	0.0	7	87.5	1	12.5	0	0.0	8	100
C11	NASOPHARYNX	0	0.0	13	86.7	2	13.3	0	0.0	15	100
C12-13	HYPOPHARYNX	0	0.0	94	95.9	3	3.1	1	1.0	98	100
C14	PHARYNX	0	0.0	1	100.0	0	0.0	0	0.0	1	100
C15	OESOPHAGUS	0	0.0	92	97.9	1	1.1	1	1.1	94	100
C16	STOMACH	0	0.0	200	92.6	16	7.4	0	0.0	216	100
C17	SMALL INTEST	0	0.0	8	88.9	1	11.1	0	0.0	9	100
C18	COLON	0	0.0	75	86.2	12	13.8	0	0.0	87	100
C19-20	RECTUM	0	0.0	109	92.4	9	7.6	0	0.0	118	100
C21	ANUS	0	0.0	22	100.0	0	0.0	0	0.0	22	100
C22	LIVER	0	0.0	36	53.7	31	46.3	0	0.0	67	100
C23-24	GALLBLAD ETC	0	0.0	47	70.1	20	29.9	0	0.0	67	100
C25	PANCREAS	0	0.0	38	61.3	24	38.7	0	0.0	62	100
C30-31	NOSE SINUS ETC	0	0.0	20	90.9	2	9.1	0	0.0	22	100
C32	LARYNX	0	0.0	7	100.0	0	0.0	0	0.0	7	100
C33-34	TRAC BRONC LUNG	0	0.0	161	82.1	35	17.9	0	0.0	196	100
C37-38	OT THORACIC ORG	0	0.0	6	100.0	0	0.0	0	0.0	6	100
C40-41	BONE	0	0.0	51	96.2	2	3.8	0	0.0	53	100
C43	MELANOMA SKIN	0	0.0	21	100.0	0	0.0	0	0.0	21	100
C44	OTHER SKIN	0	0.0	33	97.1	1	2.9	0	0.0	34	100
C47+49	CON & SOFT TISS	0	0.0	47	100.0	0	0.0	0	0.0	47	100
C50	BREAST	35	2.2	1500	93.5	69	4.3	0	0.0	1604	100
C51	VULVA	2	8.7	21	91.3	0	0.0	0	0.0	23	100
C52	VAGINA	1	2.1	45	95.7	1	2.1	0	0.0	47	100
C53	CERVIX UTERI	7	1.0	679	95.9	22	3.1	0	0.0	708	100
C54	CORPUS UTERI	0	0.0	201	99.0	2	1.0	0	0.0	203	100
C55	UTERUS UNSPECIF	0	0.0	8	100.0	0	0.0	0	0.0	8	100
C56	OVARY	0	0.0	310	89.6	36	10.4	0	0.0	346	100
C57	OT FEMALE GENIT	0	0.0	2	100.0	0	0.0	0	0.0	2	100
C58	PLACENTA	0	0.0	8	100.0	0	0.0	0	0.0	8	100
C64	KIDNEY	0	0.0	38	73.1	14	26.9	0	0.0	52	100
C66	URETER	0	0.0	1	100.0	0	0.0	0	0.0	1	100
C67	URINARY BLADDER	0	0.0	24	85.7	4	14.3	0	0.0	28	100
C68	OTHER URINARY O	0	0.0	2	100.0	0	0.0	0	0.0	2	100
C69	EYE	0	0.0	5	100.0	0	0.0	0	0.0	5	100
C70-72	BRAIN NERVOUS S	0	0.0	35	92.1	3	7.9	0	0.0	38	100
C73	THYROID	0	0.0	129	97.0	4	3.0	0	0.0	133	100
C74-75	ADRL & OT ENDO	0	0.0	5	100.0	0	0.0	0	0.0	5	100
C77	SEC LYMPH NODE	0	0.0	28	90.3	3	9.7	0	0.0	31	100
C78	SEC RESP & DIGE	0	0.0	16	72.7	6	27.3	0	0.0	22	100
C79	SEC OTHERS	0	0.0	8	44.4	10	55.6	0	0.0	18	100
C81	HODGKIN DISEASE	0	0.0	29	100.0	0	0.0	0	0.0	29	100
C82-85,96	NHL	0	0.0	107	100.0	0	0.0	0	0.0	107	100
C90	MULTIPLE MYELOM	0	0.0	33	100.0	0	0.0	0	0.0	33	100
C91	LYMPHOID LEUK	0	0.0	63	100.0	0	0.0	0	0.0	63	100
C92-94	MYELOID LEU	0	0.0	98	100.0	0	0.0	0	0.0	98	100
C95	LEU UNSPECIFIED	0	0.0	4	100.0	0	0.0	0	0.0	4	100
O&U	OT & UNCERTAIN	0	0.0	19	95.0	1	5.0	0	0.0	20	100
C00-C96	ALL SITES	78	1.5	4844	91.9	345	6.5	2	0.0	5269	100

* Others comprises endoscopy, exploratory surgery and isotopes

Appendix: 3(a) Number (#) and Proportion (%) of cancers by site ICD 10 and clinical extent of disease: 2021 – Male

ICD 10	SITE	EXTENT OF DISEASE									
		LOCALISED		REGIONAL		DISTANT		OTHERS		TOTAL	
		#	%	#	%	#	%	#	%	#	%
C00	LIP	7	30.4	9	39.1	0	0.0	7	30.4	23	100
C01-02	TONGUE	83	19.3	277	64.4	2	0.5	68	15.8	430	100
C03-06	MOUTH	58	10.1	415	72.6	6	1.0	93	16.3	572	100
C07-08	SALIVARY GL	0	0.0	9	47.4	2	10.5	8	42.1	19	100
C09	TONSIL	2	3.3	49	81.7	2	3.3	7	11.7	60	100
C10	OTHER ORPHX	1	2.1	33	68.8	2	4.2	12	25.0	48	100
C11	NASOPHARYNX	1	2.8	29	80.6	2	5.6	4	11.1	36	100
C12-13	HYPOPHARYNX	18	11.0	118	72.4	1	0.6	26	16.0	163	100
C14	PHARYNX	0	0.0	2	100.0	0	0.0	0	0.0	2	100
C15	OESOPHAGUS	0	0.0	119	64.7	40	21.7	25	13.6	184	100
C16	STOMACH	0	0.0	174	40.7	171	40.0	83	19.4	428	100
C17	SMALL INTEST	0	0.0	9	52.9	5	29.4	3	17.6	17	100
C18	COLON	3	2.3	45	34.1	38	28.8	46	34.8	132	100
C19-20	RECTUM	4	1.9	109	52.7	41	19.8	53	25.6	207	100
C21	ANUS	0	0.0	12	63.2	5	26.3	2	10.5	19	100
C22	LIVER	0	0.0	111	56.6	50	25.5	35	17.9	196	100
C23-24	GALLBLAD ETC	0	0.0	27	32.5	43	51.8	13	15.7	83	100
C25	PANCREAS	0	0.0	27	32.5	42	50.6	14	16.9	83	100
C30-31	NOSE SINUS ETC	0	0.0	19	70.4	1	3.7	7	25.9	27	100
C32	LARYNX	21	14.4	87	59.6	2	1.4	36	24.7	146	100
C33-34	TRAC BRONC LUNG	1	0.3	113	32.7	190	54.9	42	12.1	346	100
C37-38	OT THORACIC ORG	0	0.0	9	45.0	3	15.0	8	40.0	20	100
C40-41	BONE	0	0.0	44	52.4	12	14.3	28	33.3	84	100
C43	MELANOMA SKIN	0	0.0	10	47.6	3	14.3	8	38.1	21	100
C44	OTHER SKIN	1	1.9	36	66.7	4	7.4	13	24.1	54	100
C45	MESOTHELIOMA	0	0.0	0	0.0	1	100.0	0	0.0	1	100
C47+49	CON & SOFT TISS	0	0.0	19	27.5	11	15.9	39	56.5	69	100
C50	BREAST	1	10.0	4	40.0	2	20.0	3	30.0	10	100
C60	PENIS	0	0.0	37	52.1	3	4.2	31	43.7	71	100
C61	PROSTATE	4	2.5	38	24.2	54	34.4	61	38.9	157	100
C62	TESTIS	0	0.0	11	33.3	3	9.1	19	57.6	33	100
C64	KIDNEY	2	2.1	26	27.7	31	33.0	35	37.2	94	100
C66	URETER	0	0.0	0	0.0	0	0.0	3	100.0	3	100
C67	URINARY BLADDER	0	0.0	27	30.3	8	9.0	54	60.7	89	100
C68	OTHER URINARY O	0	0.0	0	0.0	1	33.3	2	66.7	3	100
C69	EYE	0	0.0	1	20.0	0	0.0	4	80.0	5	100
C70-72	BRAIN NERVOUS S	0	0.0	23	35.9	1	1.6	40	62.5	64	100
C73	THYROID	5	8.5	25	42.4	5	8.5	24	40.7	59	100
C74-75	ADRL & OT ENDO	0	0.0	3	25.0	8	66.7	1	8.3	12	100
C77	SEC LYMPH NODE	0	0.0	0	0.0	0	0.0	63	100.0	63	100
C78	SEC RESP & DIGE	0	0.0	0	0.0	0	0.0	27	100.0	27	100
C79	SEC OTHERS	0	0.0	0	0.0	0	0.0	19	100.0	19	100
C81	HODGKIN DISEASE	0	0.0	5	7.2	0	0.0	64	92.8	69	100
C82-85,96	NHL	1	0.6	13	8.3	1	0.6	142	90.4	157	100
C90	MULTIPLE MYELOM	0	0.0	0	0.0	0	0.0	65	100.0	65	100
C91	LYMPHOID LEUK	0	0.0	0	0.0	0	0.0	120	100.0	120	100
C92-94	MYELOID LEU	0	0.0	0	0.0	0	0.0	174	100.0	174	100
C95	LEU UNSPECIFIED	0	0.0	0	0.0	0	0.0	8	100.0	8	100
O&U	OT & UNCERTAIN	0	0.0	2	13.3	10	66.7	3	20.0	15	100
C00-C96	ALL SITES	213	4.4	2126	44.4	806	16.8	1642	34.3	4787	100

* Regional: Direct Extension or/and Regional nodes

§ Others: Treated elsewhere or not applicable

Appendix: 3(b) Number (#) and Proportion (%) of cancers by site ICD 10 and clinical extent of disease: 2021 - Female

ICD	SITE	EXTENT OF DISEASE									
		LOCALISED		REGIONAL*		DISTANT		OTHERS [§]		TOTAL	
		#	%	#	%	#	%	#	%	#	%
C00	LIP	2	13.3	8	53.3	0	0.0	5	33.3	15	100
C01-02	TONGUE	33	23.7	91.0	65.5	0	0.0	15	10.8	139	100
C03-06	MOUTH	12	5.9	165	80.9	2	1.0	25	12.3	204	100
C07-08	SALIVARY GL	0	0.0	5	29.4	0	0.0	12	70.6	17	100
C09	TONSIL	0	0.0	4	66.7	1	16.7	1	16.7	6	100
C10	OTHER ORPHX	0	0.0	6	75.0	0	0.0	2	25.0	8	100
C11	NASOPHARYNX	1	6.7	7	46.7	2	13.3	5	33.3	15	100
C12-13	HYPOPHARYNX	15	15.3	73	74.5	1	1.0	9	9.2	98	100
C14	PHARYNX	0	0.0	1	100.0	0	0.0	0	0.0	1	100
C15	OESOPHAGUS	0	0.0	75	79.8	15	16.0	4	4.3	94	100
C16	STOMACH	0	0.0	87	40.3	92	42.6	37	17.1	216	100
C17	SMALL INTEST	0	0.0	2	22.2	3	33.3	4	44.4	9	100
C18	COLON	3	3.4	30	34.5	26	29.9	28	32.2	87	100
C19-20	RECTUM	0	0.0	65	55.1	33	28.0	20	16.9	118	100
C21	ANUS	0	0.0	20	90.9	1	4.5	1	4.5	22	100
C22	LIVER	0	0.0	38	56.7	24	35.8	5	7.5	67	100
C23-24	GALLBLAD ETC	0	0.0	16	23.9	37	55.2	14	20.9	67	100
C25	PANCREAS	0	0.0	24	38.7	32	51.6	6	9.7	62	100
C30-31	NOSE SINUS ETC	0	0.0	16	72.7	0	0.0	6	27.3	22	100
C32	LARYNX	2	28.6	5	71.4	0	0.0	0	0.0	7	100
C33-34	TRAC BRONC LUNG	0	0.0	62	31.6	103	52.6	31	15.8	196	100
C37-38	OT THORACIC ORG	0	0.0	1	16.7	3	50.0	2	33.3	6	100
C40-41	BONE	0	0.0	26	49.1	11	20.8	16	30.2	53	100
C43	MELANOMA SKIN	0	0.0	9	42.9	1	4.8	11	52.4	21	100
C44	OTHER SKIN	0	0.0	15	44.1	2	5.9	17	50.0	34	100
C47+49	CON & SOFT TISS	0	0.0	18	38.3	5	10.6	24	51.1	47	100
C50	BREAST	62	3.9	931	58.0	258	16.1	353	22.0	1604	100
C51	VULVA	3	13.0	10	43.5	2	8.7	8	34.8	23	100
C52	VAGINA	1	2.1	34	72.3	5	10.6	7	14.9	47	100
C53	CERVIX UTERI	37	5.2	477	67.4	53	7.5	141	19.9	708	100
C54	CORPUS UTERI	50	24.6	58	28.6	19	9.4	76	37.4	203	100
C55	UTERUS UNSPECIF	0	0.0	1	12.5	0	0.0	7	87.5	8	100
C56	OVARY	16	4.6	143	41.3	78	22.5	109	31.5	346	100
C57	OT FEMALE GENIT	0	0.0	1	50.0	1	50.0	0	0.0	2	100
C58	PLACENTA	2	25.0	1	12.5	0	0.0	5	62.5	8	100
C64	KIDNEY	0	0.0	21	40.4	21	40.4	10	19.2	52	100
C66	URETER	0	0.0	0	0.0	1	100.0	0	0.0	1	100
C67	URINARY BLADDER	1	3.6	10	35.7	3	10.7	14	50.0	28	100
C68	OTHER URINARY O	0	0.0	2	100.0	0	0.0	0	0.0	2	100
C69	EYE	0	0.0	2	40.0	0	0.0	3	60.0	5	100
C70-72	BRAIN NERVOUS S	1	2.6	17	44.7	0	0.0	20	52.6	38	100
C73	THYROID	16	12.0	46	34.6	9	6.8	62	46.6	133	100
C74-75	ADRL & OT ENDO	0	0.0	3	60.0	1	20.0	1	20.0	5	100
C77	SEC LYMPH NODE	0	0.0	0	0.0	0	0.0	31	100.0	31	100
C78	SEC RESP & DIGE	0	0.0	0	0.0	0	0.0	22	100.0	22	100
C79	SEC OTHERS	0	0.0	0	0.0	0	0.0	18	100.0	18	100
C81	HODGKIN DISEASE	0	0.0	1	3.4	0	0.0	28	96.6	29	100
C82-85,96	NHL	0	0.0	8	7.5	2	1.9	97	90.7	107	100
C90	MULTIPLE MYELOM	0	0.0	0	0.0	0	0.0	33	100.0	33	100
C91	LYMPHOID LEUK	0	0.0	0	0.0	0	0.0	63	100.0	63	100
C92-94	MYELOID LEU	0	0.0	0	0.0	0	0.0	98	100.0	98	100
C95	LEU UNSPECIFIED	0	0.0	0	0.0	0	0.0	4	100.0	4	100
O&U	OT & UNCERTAIN	0	0.0	5	25.0	4	20.0	11	55.0	20	100
C00-C96	ALL SITES	257	4.9	2640	50.1	851	16.2	1521	28.9	5269	100

* Regional: Direct Extension or/and Regional nodes

§ Others: Treated elsewhere or not applicable

Appendix: 4(a) Number (#) and Proportion (%) of cancers by site ICD10 and broad treatment group: 2021 - Male

ICD 10	SITE	TREATMENT GROUP									
		PRIOR TRT		PRIOR+AT RI		ONLY AT RI		NO TRT		TOTAL	
		#	%	#	%	#	%	#	%	#	%
C00	LIP	7	30.4	0	0.0	10	43.5	6	26.1	23	100
C01-02	TONGUE	64	14.9	4	0.9	160	37.2	202	47.0	430	100
C03-06	MOUTH	86	15.0	7	1.2	207	36.2	272	47.6	572	100
C07-08	SALIVARY GL	6	31.6	1	5.3	2	10.5	10	52.6	19	100
C09	TONSIL	6	10.0	1	1.7	15	25.0	38	63.3	60	100
C10	OTHER ORPHX	12	25.0	0	0.0	3	6.2	33	68.8	48	100
C11	NASOPHARYNX	4	11.1	0	0.0	15	41.7	17	47.2	36	100
C12-13	HYPOPHARYNX	26	16.0	0	0.0	49	30.1	88	54.0	163	100
C14	PHARYNX	0	0.0	0	0.0	0	0.0	2	100.0	2	100
C15	OESOPHAGUS	24	13.0	1	0.5	36	19.6	123	66.8	184	100
C16	STOMACH	78	18.2	5	1.2	98	22.9	247	57.7	428	100
C17	SMALL INTEST	3	17.6	0	0.0	3	17.6	11	64.7	17	100
C18	COLON	43	32.6	3	2.3	37	28.0	49	37.1	132	100
C19-20	RECTUM	48	23.2	5	2.4	88	42.5	66	31.9	207	100
C21	ANUS	2	10.5	0	0.0	4	21.1	13	68.4	19	100
C22	LIVER	35	17.9	0	0.0	27	13.8	134	68.4	196	100
C23-24	GALLBLAD ETC	12	14.5	1	1.2	14	16.9	56	67.5	83	100
C25	PANCREAS	14	16.9	0	0.0	6	7.2	63	75.9	83	100
C30-31	NOSE SINUS ETC	6	22.2	1	3.7	7	25.9	13	48.1	27	100
C32	LARYNX	30	20.5	5	3.4	48	32.9	63	43.2	146	100
C33-34	TRAC BRONC LUNG	37	10.7	5	1.4	103	29.8	201	58.1	346	100
C37-38	OT THORACIC ORG	5	25.0	0	0.0	6	30.0	9	45.0	20	100
C40-41	BONE	18	21.4	10	11.9	35	41.7	21	25.0	84	100
C43	MELANOMA SKIN	8	38.1	0	0.0	4	19.0	9	42.9	21	100
C44	OTHER SKIN	10	18.5	3	5.6	20	37.0	21	38.9	54	100
C45	MESOTHELIOMA	0	0.0	0	0.0	0	0.0	1	100.0	1	100
C47+49	CON & SOFT TISS	29	42.0	10	14.5	14	20.3	16	23.2	69	100
C50	BREAST	2	20.0	1	10.0	5	50.0	2	20.0	10	100
C60	PENIS	18	25.4	13	18.3	23	32.4	17	23.9	71	100
C61	PROSTATE	38	24.2	23	14.6	52	33.1	44	28.0	157	100
C62	TESTIS	10	30.3	9	27.3	8	24.2	6	18.2	33	100
C64	KIDNEY	29	30.9	6	6.4	32	34.0	27	28.7	94	100
C66	URETER	2	66.7	1	33.3	0	0.0	0	0.0	3	100
C67	URINARY BLADDER	33	37.1	21	23.6	17	19.1	18	20.2	89	100
C68	OTHER URINARY O	2	66.7	0	0.0	0	0.0	1	33.3	3	100
C69	EYE	3	60.0	1	20.0	0	0.0	1	20.0	5	100
C70-72	BRAIN NERVOUS S	28	43.8	12	18.8	11	17.2	13	20.3	64	100
C73	THYROID	17	28.8	7	11.9	19	32.2	16	27.1	59	100
C74-75	ADRL & OT ENDO	0	0.0	1	8.3	5	41.7	6	50.0	12	100
C77	SEC LYMPH NODE	1	1.6	0	0.0	13	20.6	49	77.8	63	100
C78	SEC RESP & DIGE	0	0.0	0	0.0	1	3.7	26	96.3	27	100
C79	SEC OTHERS	0	0.0	0	0.0	2	10.5	17	89.5	19	100
C81	HODGKIN DISEASE	18	26.1	8	11.6	30	43.5	13	18.8	69	100
C82-85,96	NHL	31	19.7	3	1.9	56	35.7	67	42.7	157	100
C90	MULTIPLE MYELOM	17	26.2	1	1.5	23	35.4	24	36.9	65	100
C91	LYMPHOID LEUK	16	13.3	2	1.7	56	46.7	46	38.3	120	100
C92-94	MYELOID LEU	34	19.5	9	5.2	69	39.7	62	35.6	174	100
C95	LEU UNSPECIFIED	0	0.0	0	0.0	1	12.5	7	87.5	8	100
O&U	OT & UNCERTAIN	2	13.3	1	6.7	4	26.7	8	53.3	15	100
C00-C96	ALL SITES	914	19.1	181	3.8	1438	30.0	2254	47.1	4787	100

Appendix: 4(b) Number (#) and Proportion (%) of cancers by site ICD10 and broad treatment group: 2021 - Female

ICD	SITE	PRIOR TRT		TREATMENT GROUP				NO TRT		TOTAL	
		#	%	#	%	#	%	#	%	#	%
C00	LIP	4	26.7	1	6.7	4	26.7	6	40.0	15	100
C01-02	TONGUE	14	10.1	1	0.7	56	40.3	68	48.9	139	100
C03-06	MOUTH	23	11.3	2	1.0	58	28.4	121	59.3	204	100
C07-08	SALIVARY GL	10	58.8	2	11.8	2	11.8	3	17.6	17	100
C09	TONSIL	0	0.0	1	16.7	1	16.7	4	66.7	6	100
C10	OTHER ORPHX	2	25.0	0	0.0	1	12.5	5	62.5	8	100
C11	NASOPHARYNX	5	33.3	0	0.0	4	26.7	6	40.0	15	100
C12-13	HYPOPHARYNX	9	9.2	0	0.0	42	42.9	47	48.0	98	100
C14	PHARYNX	0	0.0	0	0.0	0	0.0	1	100.0	1	100
C15	OESOPHAGUS	4	4.3	0	0.0	28	29.8	62	66.0	94	100
C16	STOMACH	33	15.3	4	1.9	69	31.9	110	50.9	216	100
C17	SMALL INTEST	4	44.4	0	0.0	4	44.4	1	11.1	9	100
C18	COLON	24	27.6	4	4.6	29	33.3	30	34.5	87	100
C19-20	RECTUM	17	14.4	3	2.5	49	41.5	49	41.5	118	100
C21	ANUS	1	4.5	0	0.0	9	40.9	12	54.5	22	100
C22	LIVER	5	7.5	0	0.0	8	11.9	54	80.6	67	100
C23-24	GALLBLAD ETC	12	17.9	2	3.0	14	20.9	39	58.2	67	100
C25	PANCREAS	6	9.7	0	0.0	15	24.2	41	66.1	62	100
C30-31	NOSE SINUS ETC	4	18.2	2	9.1	8	36.4	8	36.4	22	100
C32	LARYNX	0	0.0	0	0.0	3	42.9	4	57.1	7	100
C33-34	TRAC BRONC LUNG	27	13.8	4	2.0	68	34.7	97	49.5	196	100
C37-38	OT THORACIC ORG	0	0.0	1	16.7	1	16.7	4	66.7	6	100
C40-41	BONE	11	20.8	5	9.4	26	49.1	11	20.8	53	100
C43	MELANOMA SKIN	10	47.6	1	4.8	4	19.0	6	28.6	21	100
C44	OTHER SKIN	14	41.2	3	8.8	6	17.6	11	32.4	34	100
C47+49	CON & SOFT TISS	18	38.3	6	12.8	11	23.4	12	25.5	47	100
C50	BREAST	308	19.2	45	2.8	736	45.9	515	32.1	1604	100
C51	VULVA	6	26.1	2	8.7	5	21.7	10	43.5	23	100
C52	VAGINA	5	10.6	2	4.3	13	27.7	27	57.4	47	100
C53	CERVIX UTERI	131	18.5	10	1.4	244	34.5	323	45.6	708	100
C54	CORPUS UTERI	56	27.6	20	9.9	77	37.9	50	24.6	203	100
C55	UTERUS UNSPECIF	6	75.0	1	12.5	0	0.0	1	12.5	8	100
C56	OVARY	80	23.1	29	8.4	127	36.7	110	31.8	346	100
C57	OT FEMALE GENIT	0	0.0	0	0.0	2	100.0	0	0.0	2	100
C58	PLACENTA	1	12.5	4	50.0	2	25.0	1	12.5	8	100
C64	KIDNEY	9	17.3	1	1.9	14	26.9	28	53.8	52	100
C66	URETER	0	0.0	0	0.0	0	0.0	1	100.0	1	100
C67	URINARY BLADDER	10	35.7	4	14.3	5	17.9	9	32.1	28	100
C68	OTHER URINARY O	0	0.0	0	0.0	1	50.0	1	50.0	2	100
C69	EYE	2	40.0	1	20.0	1	20.0	1	20.0	5	100
C70-72	BRAIN NERVOUS S	17	44.7	3	7.9	10	26.3	8	21.1	38	100
C73	THYROID	32	24.1	30	22.6	38	28.6	33	24.8	133	100
C74-75	ADRL & OT ENDO	1	20.0	0	0.0	2	40.0	2	40.0	5	100
C77	SEC LYMPH NODE	1	3.2	1	3.2	4	12.9	25	80.6	31	100
C78	SEC RESP & DIGE	0	0.0	0	0.0	2	9.1	20	90.9	22	100
C79	SEC OTHERS	3	16.7	0	0.0	1	5.6	14	77.8	18	100
C81	HODGKIN DISEASE	7	24.1	2	6.9	16	55.2	4	13.8	29	100
C82-85,96	NHL	17	15.9	4	3.7	43	40.2	43	40.2	107	100
C90	MULTIPLE MYELOM	7	21.2	1	3.0	18	54.5	7	21.2	33	100
C91	LYMPHOID LEUK	17	27.0	1	1.6	25	39.7	20	31.7	63	100
C92-94	MYELOID LEU	17	17.3	2	2.0	39	39.8	40	40.8	98	100
C95	LEU UNSPECIFIED	0	0.0	0	0.0	0	0.0	4	100.0	4	100
O&U	OT & UNCERTAIN	10	50.0	1	5.0	2	10.0	7	35.0	20	100
C00-C96	ALL SITES	1000	19.0	206	3.9	1947	37.0	2116	40.2	5269	100

Appendix 5(a): Number (#) and proportion (%) of cancers by site ICD 10 and treatment status at reporting institution (excluding the cancers previously treated): 2021 – Male

ICD 10	SITE	TREATMENT STATUS AT RI									
		RECEIVED		NOT RECED		NOT ACCEP		INCOMPLETE		TOTAL	
		#	%	#	%	#	%	#	%	#	%
C00	LIP	10	62.5	5	31.2	0	0.0	1	6.2	16	100
C01-02	TONGUE	160	44.2	196	54.1	0	0.0	6	1.7	362	100
C03-06	MOUTH	207	43.2	267	55.7	0	0.0	5	1.0	479	100
C07-08	SALIVARY GL	2	16.7	10	83.3	0	0.0	0	0.0	12	100
C09	TONSIL	15	28.3	36	67.9	0	0.0	2	3.8	53	100
C10	OTHER ORPHX	3	8.3	33	91.7	0	0.0	0	0.0	36	100
C11	NASOPHARYNX	15	46.9	16	50.0	0	0.0	1	3.1	32	100
C12-13	HYPOPHARYNX	49	35.8	88	64.2	0	0.0	0	0.0	137	100
C14	PHARYNX	0	0.0	2	100.0	0	0.0	0	0.0	2	100
C15	OESOPHAGUS	36	22.6	119	74.8	1	0.6	3	1.9	159	100
C16	STOMACH	98	28.4	231	67.0	5	1.4	11	3.2	345	100
C17	SMALL INTEST	3	21.4	11	78.6	0	0.0	0	0.0	14	100
C18	COLON	37	43.0	43	50.0	2	2.3	4	4.7	86	100
C19-20	RECTUM	88	57.1	64	41.6	0	0.0	2	1.3	154	100
C21	ANUS	4	23.5	12	70.6	0	0.0	1	5.9	17	100
C22	LIVER	27	16.8	127	78.9	1	0.6	6	3.7	161	100
C23-24	GALLBLAD ETC	14	20.0	55	78.6	0	0.0	1	1.4	70	100
C25	PANCREAS	6	8.7	61	88.4	0	0.0	2	2.9	69	100
C30-31	NOSE SINUS ETC	7	35.0	13	65.0	0	0.0	0	0.0	20	100
C32	LARYNX	48	43.2	62	55.9	0	0.0	1	0.9	111	100
C33-34	TRAC BRONC LUNG	103	33.9	181	59.5	1	0.3	19	6.2	304	100
C37-38	OT THORACIC ORG	6	40.0	6	40.0	0	0.0	3	20.0	15	100
C40-41	BONE	35	62.5	20	35.7	0	0.0	1	1.8	56	100
C43	MELANOMA SKIN	4	30.8	9	69.2	0	0.0	0	0.0	13	100
C44	OTHER SKIN	20	48.8	20	48.8	0	0.0	1	2.4	41	100
C45	MESOTHELIOMA	0	0.0	0	0.0	0	0.0	1	100.0	1	100
C47+49	CON & SOFT TISS	14	46.7	16	53.3	0	0.0	0	0.0	30	100
C50	BREAST	5	71.4	2	28.6	0	0.0	0	0.0	7	100
C60	PENIS	23	57.5	17	42.5	0	0.0	0	0.0	40	100
C61	PROSTATE	52	54.2	44	45.8	0	0.0	0	0.0	96	100
C62	TESTIS	8	57.1	6	42.9	0	0.0	0	0.0	14	100
C64	KIDNEY	32	54.2	26	44.1	0	0.0	1	1.7	59	100
C67	URINARY BLADDER	17	48.6	17	48.6	1	2.9	0	0.0	35	100
C68	OTHER URINARY O	0	0.0	1	100.0	0	0.0	0	0.0	1	100
C69	EYE	0	0.0	1	100.0	0	0.0	0	0.0	1	100
C70-72	BRAIN NERVOUS S	11	45.8	12	50.0	0	0.0	1	4.2	24	100
C73	THYROID	19	54.3	16	45.7	0	0.0	0	0.0	35	100
C74-75	ADRL & OT ENDO	5	45.5	4	36.4	0	0.0	2	18.2	11	100
C77	SEC LYMPH NODE	13	21.0	49	79.0	0	0.0	0	0.0	62	100
C78	SEC RESP & DIGE	1	3.7	25	92.6	1	3.7	0	0.0	27	100
C79	SEC OTHERS	2	10.5	16	84.2	1	5.3	0	0.0	19	100
C81	HODGKIN DISEASE	30	69.8	11	25.6	0	0.0	2	4.7	43	100
C82-85,96	NHL	56	45.5	51	41.5	1	0.8	15	12.2	123	100
C90	MULTIPLE MYELOM	23	48.9	17	36.2	0	0.0	7	14.9	47	100
C91	LYMPHOID LEUK	56	54.9	42	41.2	0	0.0	4	3.9	102	100
C92-94	MYELOID LEU	69	52.7	47	35.9	0	0.0	15	11.5	131	100
C95	LEU UNSPECIFIED	1	12.5	7	87.5	0	0.0	0	0.0	8	100
O&U	OT & UNCERTAIN	4	33.3	8	66.7	0	0.0	0	0.0	12	100
C00-C96	ALL SITES	1438	38.9	2122	57.5	14	0.4	118	3.2	3692	100

Appendix 5(b): Number (#) and proportion (%) of cancers by site ICD 10 and treatment status at reporting institution (excluding the cancers previously treated): 2021 - Female

ICD 10	SITE	TREATMENT STATUS AT RI									
		RECEIVED		NOT RECED		NOT ACCEP		INCOMPLETE		TOTAL	
		#	%	#	%	#	%	#	%	#	%
C00	LIP	4	40.0	5	50.0	0	0.0	1	10.0	10	100
C01-02	TONGUE	56	45.2	68	54.8	0	0.0	0	0.0	124	100
C03-06	MOUTH	58	32.4	116	64.8	0	0.0	5	2.8	179	100
C07-08	SALIVARY GL	2	40.0	3	60.0	0	0.0	0	0.0	5	100
C09	TONSIL	1	20.0	4	80.0	0	0.0	0	0.0	5	100
C10	OTHER ORPHX	1	16.7	5	83.3	0	0.0	0	0.0	6	100
C11	NASOPHARYNX	4	40.0	6	60.0	0	0.0	0	0.0	10	100
C12-13	HYPOPHARYNX	42	47.2	47	52.8	0	0.0	0	0.0	89	100
C14	PHARYNX	0	0.0	1	100.0	0	0.0	0	0.0	1	100
C15	OESOPHAGUS	28	31.1	60	66.7	2	2.2	0	0.0	90	100
C16	STOMACH	69	38.5	97	54.2	2	1.1	11	6.1	179	100
C17	SMALL INTEST	4	80.0	1	20.0	0	0.0	0	0.0	5	100
C18	COLON	29	49.2	28	47.5	0	0.0	2	3.4	59	100
C19-20	RECTUM	49	50.0	45	45.9	0	0.0	4	4.1	98	100
C21	ANUS	9	42.9	12	57.1	0	0.0	0	0.0	21	100
C22	LIVER	8	12.9	50	80.6	0	0.0	4	6.5	62	100
C23-24	GALLBLAD ETC	14	26.4	36	67.9	0	0.0	3	5.7	53	100
C25	PANCREAS	15	26.8	37	66.1	1	1.8	3	5.4	56	100
C30-31	NOSE SINUS ETC	8	50.0	8	50.0	0	0.0	0	0.0	16	100
C32	LARYNX	3	42.9	4	57.1	0	0.0	0	0.0	7	100
C33-34	TRAC BRONC LUNG	68	41.2	82	49.7	0	0.0	15	9.1	165	100
C37-38	OT THORACIC ORG	1	20.0	4	80.0	0	0.0	0	0.0	5	100
C40-41	BONE	26	70.3	10	27.0	0	0.0	1	2.7	37	100
C43	MELANOMA SKIN	4	40.0	6	60.0	0	0.0	0	0.0	10	100
C44	OTHER SKIN	6	35.3	11	64.7	0	0.0	0	0.0	17	100
C47+49	CON & SOFT TISS	11	47.8	12	52.2	0	0.0	0	0.0	23	100
C50	BREAST	736	58.8	482	38.5	0	0.0	33	2.6	1251	100
C51	VULVA	5	33.3	10	66.7	0	0.0	0	0.0	15	100
C52	VAGINA	13	32.5	26	65.0	1	2.5	0	0.0	40	100
C53	CERVIX UTERI	244	43.0	306	54.0	0	0.0	17	3.0	567	100
C54	CORPUS UTERI	77	60.6	45	35.4	1	0.8	4	3.1	127	100
C55	UTERUS UNSPECIF	0	0.0	1	100.0	0	0.0	0	0.0	1	100
C56	OVARY	127	53.6	100	42.2	1	0.4	9	3.8	237	100
C57	OT FEMALE GENIT	2	100.0	0	0.0	0	0.0	0	0.0	2	100
C58	PLACENTA	2	66.7	1	33.3	0	0.0	0	0.0	3	100
C64	KIDNEY	14	33.3	28	66.7	0	0.0	0	0.0	42	100
C66	URETER	0	0.0	1	100.0	0	0.0	0	0.0	1	100
C67	URINARY BLADDER	5	35.7	9	64.3	0	0.0	0	0.0	14	100
C68	OTHER URINARY O	1	50.0	1	50.0	0	0.0	0	0.0	2	100
C69	EYE	1	50.0	1	50.0	0	0.0	0	0.0	2	100
C70-72	BRAIN NERVOUS S	10	55.6	7	38.9	0	0.0	1	5.6	18	100
C73	THYROID	38	53.5	31	43.7	1	1.4	1	1.4	71	100
C74-75	ADRL & OT ENDO	2	50.0	1	25.0	1	25.0	0	0.0	4	100
C77	SEC LYMPH NODE	4	13.8	25	86.2	0	0.0	0	0.0	29	100
C78	SEC RESP & DIGE	2	9.1	20	90.9	0	0.0	0	0.0	22	100
C79	SEC OTHERS	1	6.7	14	93.3	0	0.0	0	0.0	15	100
C81	HODGKIN DISEASE	16	80.0	4	20.0	0	0.0	0	0.0	20	100
C82-85,96	NHL	43	50.0	30	34.9	0	0.0	13	15.1	86	100
C90	MULTIPLE MYELOM	18	72.0	5	20.0	0	0.0	2	8.0	25	100
C91	LYMPHOID LEUK	25	55.6	18	40.0	0	0.0	2	4.4	45	100
C92-94	MYELOID LEU	39	49.4	33	41.8	0	0.0	7	8.9	79	100
C95	LEU UNSPECIFIED	0	0.0	4	100.0	0	0.0	0	0.0	4	100
O&U	OT & UNCERTAIN	2	22.2	6	66.7	1	11.1	0	0.0	9	100
C00-C96	ALL SITES	1947	47.9	1967	48.4	11	0.3	138	3.4	4063	100

Appendix 6(a): Number (#) and Proportion (%) of cancer by site (ICD 10) and type of treatments at Reporting Institution (Excluding the cancers previously treated): 2021 - Male

ICD 10	SITE	TYPE OF TREATMENT GIVEN AT RI																	
		SURGERY		R-THERAPY		C-THERAPY		S+R		S+C		R+C		S+C+R		OTHERS		TOTAL	
		#	%	#	%	#	%	#	%	#	%	#	%	#	%	#	%	#	%
C00	LIP	1	10.0	4	40.0	0	0.0	0	0.0	0	0.0	2	20.0	3	30.0	0	0.0	10	100
C01-02	TONGUE	26	16.2	23	14.4	1	0.6	18	11.2	0	0.0	88	55.0	4	2.5	0	0.0	160	100
C03-06	MOUTH	27	13.0	31	15.0	0	0.0	31	15.0	0	0.0	98	47.3	20	9.7	0	0.0	207	100
C07-08	SALIVARY GL	0	0.0	1	50.0	1	50.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	2	100
C09	TONSIL	0	0.0	5	33.3	0	0.0	1	6.7	0	0.0	9	60.0	0	0.0	0	0.0	15	100
C10	OTHER ORPHX	0	0.0	1	33.3	0	0.0	0	0.0	0	0.0	2	66.7	0	0.0	0	0.0	3	100
C11	NASOPHARYNX	0	0.0	1	6.7	0	0.0	0	0.0	0	0.0	14	93.3	0	0.0	0	0.0	15	100
C12-13	HYPOPHARYNX	0	0.0	11	22.4	0	0.0	0	0.0	0	0.0	37	75.5	1	2.0	0	0.0	49	100
C15	OESOPHAGUS	0	0.0	6	16.7	6	16.7	0	0.0	0	0.0	20	55.6	4	11.1	0	0.0	36	100
C16	STOMACH	2	2.0	1	1.0	53	54.1	0	0.0	38	38.8	2	2.0	2	2.0	0	0.0	98	100
C17	SMALL INTEST	0	0.0	0	0.0	2	66.7	0	0.0	0	0.0	0	0.0	0	0.0	1	33.3	3	100
C18	COLON	9	24.3	0	0.0	13	35.1	0	0.0	12	32.4	2	5.4	1	2.7	0	0.0	37	100
C19-20	RECTUM	3	3.4	3	3.4	10	11.4	0	0.0	4	4.5	34	38.6	33	37.5	1	1.1	88	100
C21	ANUS	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	4	100.0	0	0.0	0	0.0	4	100
C22	LIVER	3	11.1	0	0.0	8	29.6	0	0.0	4	14.8	1	3.7	0	0.0	11	40.7	27	100
C23-24	GALLBLAD ETC	2	14.3	0	0.0	5	35.7	0	0.0	7	50.0	0	0.0	0	0.0	0	0.0	14	100
C25	PANCREAS	2	33.3	1	16.7	1	16.7	0	0.0	0	0.0	2	33.3	0	0.0	0	0.0	6	100
C30-31	NOSE SINUS ETC	0	0.0	1	14.3	0	0.0	2	28.6	1	14.3	2	28.6	1	14.3	0	0.0	7	100
C32	LARYNX	4	8.3	17	35.4	1	2.1	9	18.8	0	0.0	15	31.2	2	4.2	0	0.0	48	100
C33-34	TRAC BRONC LUNG	1	1.0	1	1.0	43	41.7	0	0.0	1	1.0	39	37.9	1	1.0	17	16.5	103	100
C37-38	OT THORACIC ORG	1	16.7	0	0.0	2	33.3	0	0.0	2	33.3	1	16.7	0	0.0	0	0.0	6	100
C40-41	BONE	5	14.3	1	2.9	3	8.6	1	2.9	17	48.6	3	8.6	5	14.3	0	0.0	35	100
C43	MELANOMA SKIN	4	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	4	100
C44	OTHER SKIN	16	80.0	2	10.0	0	0.0	0	0.0	1	5.0	1	5.0	0	0.0	0	0.0	20	100
C47+49	CON & SOFT TISS	2	14.3	0	0.0	5	35.7	2	14.3	2	14.3	2	14.3	1	7.1	0	0.0	14	100
C50	BREAST	0	0.0	0	0.0	1	20.0	0	0.0	0	0.0	0	0.0	0	0.0	4	80.0	5	100
C60	PENIS	17	73.9	0	0.0	3	13.0	0	0.0	2	8.7	0	0.0	0	0.0	1	4.3	23	100
C61	PROSTATE	3	5.8	0	0.0	0	0.0	1	1.9	1	1.9	0	0.0	0	0.0	47	90.4	52	100
C62	TESTIS	0	0.0	0	0.0	1	12.5	0	0.0	7	87.5	0	0.0	0	0.0	0	0.0	8	100
C64	KIDNEY	18	56.2	0	0.0	3	9.4	0	0.0	1	3.1	2	6.2	1	3.1	7	21.9	32	100
C67	URINARY BLADDER	8	47.1	0	0.0	0	0.0	1	5.9	7	41.2	0	0.0	1	5.9	0	0.0	17	100
C70-72	BRAIN NERVOUS S	4	36.4	0	0.0	1	9.1	1	9.1	0	0.0	0	0.0	5	45.5	0	0.0	11	100
C73	THYROID	1	5.3	0	0.0	0	0.0	1	5.3	0	0.0	1	5.3	1	5.3	15	78.9	19	100
C74-75	ADRL & OT ENDO	1	20.0	0	0.0	0	0.0	0	0.0	3	60.0	0	0.0	1	20.0	0	0.0	5	100
C77	SEC LYMPH NODE	0	0.0	3	23.1	2	15.4	0	0.0	0	0.0	8	61.5	0	0.0	0	0.0	13	100
C78	SEC RESP & DIGE	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	100.0	0	0.0	0	0.0	1	100
C79	SEC OTHERS	1	50.0	0	0.0	1	50.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	2	100
C81	HODGKIN DISEASE	0	0.0	1	3.3	24	80.0	0	0.0	0	0.0	5	16.7	0	0.0	0	0.0	30	100
C82-85,96	NHL	0	0.0	0	0.0	41	73.2	0	0.0	0	0.0	15	26.8	0	0.0	0	0.0	56	100
C90	MULTIPLE MYELOM	0	0.0	0	0.0	14	60.9	0	0.0	0	0.0	8	34.8	0	0.0	1	4.3	23	100
C91	LYMPHOID LEUK	0	0.0	0	0.0	42	75.0	0	0.0	0	0.0	14	25.0	0	0.0	0	0.0	56	100
C92-94	MYELOID LEU	0	0.0	0	0.0	65	94.2	0	0.0	0	0.0	2	2.9	0	0.0	2	2.9	69	100
C95	LEU UNSPECIFIED	0	0.0	0	0.0	1	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	100
O&U	OT & UNCERTAIN	2	50.0	0	0.0	1	25.0	0	0.0	1	25.0	0	0.0	0	0.0	0	0.0	4	100
C00-C96	ALL SITES	163	11.3	114	7.9	354	24.6	68	4.7	111	7.7	434	30.2	87	6.1	107	7.4	1438	100

Appendix 6(b): Number (#) and Proportion (%) of cancer by site (ICD 10) and type of treatment at Reporting Institution (Excluding the cancers previously treated): 2021 - Female

ICD 10	SITE	TYPE OF TREATMENT GIVEN AT RI																	
		SURGERY		R-THERAPY		C-THERAPY		S+R		S+C		R+C		S+C+R		OTHERS		TOTAL	
		#	%	#	%	#	%	#	%	#	%	#	%	#	%	#	%	#	%
C00	LIP	1	25.0	1	25.0	0	0.0	0	0.0	0	0.0	1	25.0	1	25.0	0	0.0	4	100
C01-02	TONGUE	18	32.1	4	7.1	0	0.0	8	14.3	0	0.0	26	46.4	0	0.0	0	0.0	56	100
C03-06	MOUTH	7	12.1	10	17.2	0	0.0	10	17.2	0	0.0	27	46.6	4	6.9	0	0.0	58	100
C07-08	SALIVARY GL	2	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	2	100
C09	TONSIL	0	0.0	1	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	100
C10	OTHER ORPHX	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	100.0	0	0.0	0	0.0	1	100
C11	NASOPHARYNX	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	4	100.0	0	0.0	0	0.0	4	100
C12-13	HYPOPHARYNX	1	2.4	4	9.5	1	2.4	3	7.1	0	0.0	32	76.2	1	2.4	0	0.0	42	100
C15	OESOPHAGUS	0	0.0	1	3.6	2	7.1	0	0.0	0	0.0	18	64.3	7	25.0	0	0.0	28	100
C16	STOMACH	2	2.9	0	0.0	39	56.5	0	0.0	23	33.3	4	5.8	1	1.4	0	0.0	69	100
C17	SMALL INTEST	1	25.0	0	0.0	1	25.0	0	0.0	2	50.0	0	0.0	0	0.0	0	0.0	4	100
C18	COLON	10	34.5	0	0.0	7	24.1	1	3.4	11	37.9	0	0.0	0	0.0	0	0.0	29	100
C19-20	RECTUM	2	4.1	4	8.2	12	24.5	0	0.0	4	8.2	13	26.5	14	28.6	0	0.0	49	100
C21	ANUS	0	0.0	3	33.3	0	0.0	0	0.0	0	0.0	5	55.6	1	11.1	0	0.0	9	100
C22	LIVER	0	0.0	0	0.0	4	50.0	0	0.0	1	12.5	0	0.0	0	0.0	3	37.5	8	100
C23-24	GALLBLAD ETC	3	21.4	0	0.0	6	42.9	0	0.0	4	28.6	1	7.1	0	0.0	0	0.0	14	100
C25	PANCREAS	1	6.7	2	13.3	7	46.7	0	0.0	1	6.7	2	13.3	0	0.0	2	13.3	15	100
C30-31	NOSE SINUS ETC	0	0.0	2	25.0	0	0.0	1	12.5	0	0.0	2	25.0	3	37.5	0	0.0	8	100
C32	LARYNX	1	33.3	1	33.3	0	0.0	0	0.0	0	0.0	1	33.3	0	0.0	0	0.0	3	100
C33-34	TRAC BRONC LUNG	3	4.4	0	0.0	19	27.9	0	0.0	3	4.4	20	29.4	0	0.0	23	33.8	68	100
C37-38	OT THORACIC ORG	1	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	100
C40-41	BONE	3	11.5	0	0.0	5	19.2	0	0.0	12	46.2	3	11.5	3	11.5	0	0.0	26	100
C43	MELANOMA SKIN	4	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	4	100
C44	OTHER SKIN	5	83.3	0	0.0	1	16.7	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	6	100
C47+49	CON & SOFT TISS	3	27.3	0	0.0	0	0.0	1	9.1	1	9.1	3	27.3	2	18.2	1	9.1	11	100
C50	BREAST	18	2.4	1	0.1	32	4.3	4	0.5	40	5.4	15	2.0	102	13.9	524	71.2	736	100
C51	VULVA	2	40.0	2	40.0	1	20.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	5	100
C52	VAGINA	1	7.7	7	53.8	1	7.7	0	0.0	0	0.0	4	30.8	0	0.0	0	0.0	13	100
C53	CERVIX UTERI	2	0.8	57	23.4	13	5.3	1	0.4	0	0.0	158	64.8	13	5.3	0	0.0	244	100
C54	CORPUS UTERI	26	33.8	1	1.3	3	3.9	12	15.6	15	19.5	0	0.0	13	16.9	7	9.1	77	100
C56	OVARY	8	6.3	0	0.0	28	22.0	0	0.0	89	70.1	0	0.0	0	0.0	2	1.6	127	100
C57	OT FEMALE GENIT	0	0.0	0	0.0	0	0.0	0	0.0	1	50.0	0	0.0	0	0.0	1	50.0	2	100
C58	PLACENTA	0	0.0	0	0.0	1	50.0	0	0.0	1	50.0	0	0.0	0	0.0	0	0.0	2	100
C64	KIDNEY	6	42.9	0	0.0	1	7.1	0	0.0	2	14.3	0	0.0	0	0.0	5	35.7	14	100
C67	URINARY BLADDER	3	60.0	0	0.0	0	0.0	0	0.0	2	40.0	0	0.0	0	0.0	0	0.0	5	100
C68	OTHER URINARY O	0	0.0	0	0.0	0	0.0	1	100.0	0	0.0	0	0.0	0	0.0	0	0.0	1	100
C69	EYE	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	100.0	0	0.0	1	100
C70-72	BRAIN NERVOUS S	5	50.0	0	0.0	0	0.0	2	20.0	0	0.0	0	0.0	3	30.0	0	0.0	10	100
C73	THYROID	6	15.8	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	32	84.2	38	100
C74-75	ADRL & OT ENDO	0	0.0	0	0.0	1	50.0	0	0.0	0	0.0	0	0.0	1	50.0	0	0.0	2	100
C77	SEC LYMPH NODE	0	0.0	1	25.0	1	25.0	0	0.0	1	25.0	1	25.0	0	0.0	0	0.0	4	100
C78	SEC RESP & DIGE	1	50.0	0	0.0	1	50.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	2	100
C79	SEC OTHERS	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	100.0	0	0.0	0	0.0	1	100
C81	HODGKIN DISEASE	0	0.0	0	0.0	14	87.5	0	0.0	0	0.0	2	12.5	0	0.0	0	0.0	16	100
C82-85,96	NHL	0	0.0	1	2.3	35	81.4	0	0.0	0	0.0	7	16.3	0	0.0	0	0.0	43	100
C90	MULTIPLE MYELOM	0	0.0	0	0.0	13	72.2	0	0.0	0	0.0	5	27.8	0	0.0	0	0.0	18	100
C91	LYMPHOID LEUK	0	0.0	0	0.0	23	92.0	0	0.0	0	0.0	2	8.0	0	0.0	0	0.0	25	100
C92-94	MYELOID LEU	0	0.0	0	0.0	39	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	39	100
O&U	OT & UNCERTAIN	0	0.0	0	0.0	1	50.0	0	0.0	1	50.0	0	0.0	0	0.0	0	0.0	2	100
C00-C96	ALL SITES	146	7.5	103	5.3	312	16.0	44	2.3	214	11.0	358	18.4	170	8.7	600	30.8	1947	100

Appendix 7(a): Number (#) and Proportion (%) of cancer by site (ICD 10) and any treatment administered at Reporting Institution (Excluding the cancers previously treated): 2021 - Male

ICD 10	SITE	TYPE OF ANY TREATMENT GIVEN AT RI										Total	
		Surgery		Radiotherapy		Chemotherapy		Hormone		Others			
		No	%	No	%	No	%	No	%	No	%	No	%
C00	LIP	4	20.0	10	50.0	6	30.0	0	0.0	0	0.0	20	100
C01-02	TONGUE	48	17.0	138	48.8	97	34.3	0	0.0	0	0.0	283	100
C03-06	MOUTH	78	20.3	185	48.2	121	31.5	0	0.0	0	0.0	384	100
C07-08	SALIVARY GL	0	0.0	1	50.0	1	50.0	0	0.0	0	0.0	2	100
C09	TONSIL	1	3.4	17	58.6	11	37.9	0	0.0	0	0.0	29	100
C10	OTHER ORPHX	0	0.0	3	60.0	2	40.0	0	0.0	0	0.0	5	100
C11	NASOPHARYNX	0	0.0	16	53.3	14	46.7	0	0.0	0	0.0	30	100
C12-13	HYPOPHARYNX	1	1.1	49	55.7	38	43.2	0	0.0	0	0.0	88	100
C15	OESOPHAGUS	4	5.8	32	46.4	33	47.8	0	0.0	0	0.0	69	100
C16	STOMACH	42	27.5	5	3.3	106	69.3	0	0.0	0	0.0	153	100
C17	SMALL INTEST	0	0.0	0	0.0	2	66.7	1	33.3	0	0.0	3	100
C18	COLON	22	38.6	3	5.3	32	56.1	0	0.0	0	0.0	57	100
C19-20	RECTUM	40	20.6	70	36.1	83	42.8	1	0.5	0	0.0	194	100
C21	ANUS	0	0.0	5	50.0	5	50.0	0	0.0	0	0.0	10	100
C22	LIVER	7	18.4	1	2.6	15	39.5	0	0.0	15	39.5	38	100
C23-24	GALLBLAD ETC	10	45.5	0	0.0	12	54.5	0	0.0	0	0.0	22	100
C25	PANCREAS	2	20.0	3	30.0	5	50.0	0	0.0	0	0.0	10	100
C30-31	NOSE SINUS ETC	4	28.6	6	42.9	4	28.6	0	0.0	0	0.0	14	100
C32	LARYNX	15	19.2	44	56.4	19	24.4	0	0.0	0	0.0	78	100
C33-34	TRAC BRONC LUNG	3	1.8	44	26.5	100	60.2	0	0.0	19	11.4	166	100
C37-38	OT THORACIC ORG	3	25.0	1	8.3	8	66.7	0	0.0	0	0.0	12	100
C40-41	BONE	28	41.8	10	14.9	29	43.3	0	0.0	0	0.0	67	100
C43	MELANOMA SKIN	4	100.0	0	0.0	0	0.0	0	0.0	0	0.0	4	100
C44	OTHER SKIN	17	73.9	3	13.0	3	13.0	0	0.0	0	0.0	23	100
C45	MESOTHELIOMA	0	0.0	0	0.0	1	100.0	0	0.0	0	0.0	1	100
C47+49	CON & SOFT TISS	7	31.8	5	22.7	10	45.5	0	0.0	0	0.0	22	100
C50	BREAST	4	26.7	2	13.3	5	33.3	4	26.7	0	0.0	15	100
C60	PENIS	19	73.1	1	3.8	5	19.2	1	3.8	0	0.0	26	100
C61	PROSTATE	13	14.1	17	18.5	15	16.3	45	48.9	2	2.2	92	100
C62	TESTIS	7	46.7	0	0.0	8	53.3	0	0.0	0	0.0	15	100
C64	KIDNEY	21	53.8	4	10.3	7	17.9	0	0.0	7	17.9	39	100
C67	URINARY BLADDER	17	63.0	2	7.4	8	29.6	0	0.0	0	0.0	27	100
C70-72	BRAIN NERVOUS S	11	47.8	6	26.1	6	26.1	0	0.0	0	0.0	23	100
C73	THYROID	18	36.7	14	28.6	2	4.1	15	30.6	0	0.0	49	100
C74-75	ADRL & OT ENDO	5	41.7	1	8.3	6	50.0	0	0.0	0	0.0	12	100
C77	SEC LYMPH NODE	0	0.0	11	52.4	10	47.6	0	0.0	0	0.0	21	100
C78	SEC RESP & DIGE	0	0.0	1	50.0	1	50.0	0	0.0	0	0.0	2	100
C79	SEC OTHERS	1	50.0	0	0.0	1	50.0	0	0.0	0	0.0	2	100
C81	HODGKIN DISEASE	0	0.0	6	16.2	31	83.8	0	0.0	0	0.0	37	100
C82-85,96	NHL	0	0.0	15	17.4	71	82.6	0	0.0	0	0.0	86	100
C90	MULTIPLE MYELOM	2	5.0	8	20.0	28	70.0	0	0.0	2	5.0	40	100
C91	LYMPHOID LEUK	0	0.0	15	20.0	60	80.0	0	0.0	0	0.0	75	100
C92-94	MYELOID LEU	0	0.0	2	2.3	82	95.3	0	0.0	2	2.3	86	100
C95	LEU UNSPECIFIED	0	0.0	0	0.0	1	100.0	0	0.0	0	0.0	1	100
O&U	OT & UNCERTAIN	3	60.0	0	0.0	2	40.0	0	0.0	0	0.0	5	100
C00-C96	ALL SITES	461	18.9	756	31.0	1106	45.4	67	2.7	47	1.9	2437	100

Appendix 7(b): Number (#) and Proportion (%) of cancer by site (ICD 10) and any treatment administered at Reporting Institution (Excluding the cancers previously treated): 2021 - Female

ICD 10	SITE	TYPE OF ANY TREATMENT GIVEN AT RI										Total	
		Surgery		Radiotherapy		Chemotherapy		Hormone		Others			
		No	%	No	%	No	%	No	%	No	%	No	%
C00	LIP	2	22.2	4	44.4	3	33.3	0	0.0	0	0.0	9	100
C01-02	TONGUE	26	28.9	38	42.2	26	28.9	0	0.0	0	0.0	90	100
C03-06	MOUTH	21	18.6	56	49.6	36	31.9	0	0.0	0	0.0	113	100
C07-08	SALIVARY GL	2	100.0	0	0.0	0	0.0	0	0.0	0	0.0	2	100
C09	TONSIL	0	0.0	1	100.0	0	0.0	0	0.0	0	0.0	1	100
C10	OTHER ORPHX	0	0.0	1	50.0	1	50.0	0	0.0	0	0.0	2	100
C11	NASOPHARYNX	0	0.0	4	50.0	4	50.0	0	0.0	0	0.0	8	100
C12-13	HYPOPHARYNX	5	6.3	40	50.6	34	43.0	0	0.0	0	0.0	79	100
C15	OESOPHAGUS	7	11.7	26	43.3	27	45.0	0	0.0	0	0.0	60	100
C16	STOMACH	26	23.9	5	4.6	78	71.6	0	0.0	0	0.0	109	100
C17	SMALL INTEST	3	50.0	0	0.0	3	50.0	0	0.0	0	0.0	6	100
C18	COLON	22	51.2	1	2.3	20	46.5	0	0.0	0	0.0	43	100
C19-20	RECTUM	21	21.2	32	32.3	46	46.5	0	0.0	0	0.0	99	100
C21	ANUS	1	6.2	9	56.2	6	37.5	0	0.0	0	0.0	16	100
C22	LIVER	1	7.7	0	0.0	9	69.2	0	0.0	3	23.1	13	100
C23-24	GALLBLAD ETC	8	34.8	1	4.3	14	60.9	0	0.0	0	0.0	23	100
C25	PANCREAS	2	9.5	4	19.0	13	61.9	0	0.0	2	9.5	21	100
C30-31	NOSE SINUS ETC	4	23.5	8	47.1	5	29.4	0	0.0	0	0.0	17	100
C32	LARYNX	1	25.0	2	50.0	1	25.0	0	0.0	0	0.0	4	100
C33-34	TRAC BRONC LUNG	6	5.7	20	18.9	54	50.9	0	0.0	26	24.5	106	100
C37-38	OT THORACIC ORG	1	100.0	0	0.0	0	0.0	0	0.0	0	0.0	1	100
C40-41	BONE	18	37.5	6	12.5	24	50.0	0	0.0	0	0.0	48	100
C43	MELANOMA SKIN	4	100.0	0	0.0	0	0.0	0	0.0	0	0.0	4	100
C44	OTHER SKIN	5	83.3	0	0.0	1	16.7	0	0.0	0	0.0	6	100
C47+49	CON & SOFT TISS	7	35.0	6	30.0	6	30.0	0	0.0	1	5.0	20	100
C50	BREAST	588	26.8	445	20.3	629	28.7	528	24.1	0	0.0	2190	100
C51	VULVA	2	40.0	2	40.0	1	20.0	0	0.0	0	0.0	5	100
C52	VAGINA	1	5.9	11	64.7	5	29.4	0	0.0	0	0.0	17	100
C53	CERVIX UTERI	16	3.5	245	53.3	199	43.3	0	0.0	0	0.0	460	100
C54	CORPUS UTERI	73	49.3	32	21.6	35	23.6	8	5.4	0	0.0	148	100
C56	OVARY	98	43.0	1	0.4	127	55.7	2	0.9	0	0.0	228	100
C57	OT FEMALE GENIT	1	25.0	0	0.0	2	50.0	1	25.0	0	0.0	4	100
C58	PLACENTA	1	33.3	0	0.0	2	66.7	0	0.0	0	0.0	3	100
C64	KIDNEY	8	50.0	0	0.0	3	18.8	0	0.0	5	31.2	16	100
C67	URINARY BLADDER	5	71.4	0	0.0	2	28.6	0	0.0	0	0.0	7	100
C68	OTHER URINARY O	1	50.0	1	50.0	0	0.0	0	0.0	0	0.0	2	100
C69	EYE	1	33.3	1	33.3	1	33.3	0	0.0	0	0.0	3	100
C70-72	BRAIN NERVOUS S	11	57.9	5	26.3	3	15.8	0	0.0	0	0.0	19	100
C73	THYROID	38	39.2	26	26.8	1	1.0	32	33.0	0	0.0	97	100
C74-75	ADRL & OT ENDO	1	25.0	1	25.0	2	50.0	0	0.0	0	0.0	4	100
C77	SEC LYMPH NODE	1	16.7	2	33.3	3	50.0	0	0.0	0	0.0	6	100
C78	SEC RESP & DIGE	1	50.0	0	0.0	1	50.0	0	0.0	0	0.0	2	100
C79	SEC OTHERS	0	0.0	1	50.0	1	50.0	0	0.0	0	0.0	2	100
C81	HODGKIN DISEASE	0	0.0	2	11.1	16	88.9	0	0.0	0	0.0	18	100
C82-85,96	NHL	0	0.0	8	12.7	55	87.3	0	0.0	0	0.0	63	100
C90	MULTIPLE MYELOM	0	0.0	5	20.0	20	80.0	0	0.0	0	0.0	25	100
C91	LYMPHOID LEUK	0	0.0	2	6.9	27	93.1	0	0.0	0	0.0	29	100
C92-94	MYELOID LEU	0	0.0	0	0.0	46	100.0	0	0.0	0	0.0	46	100
O&U	OT & UNCERTAIN	1	33.3	0	0.0	2	66.7	0	0.0	0	0.0	3	100
C00-C96	ALL SITES	1041	24.2	1054	24.5	1594	37.1	571	13.3	37	0.9	4297	100

Appendix 8: Classification of Childhood Cancers : 2021

Cancer pattern	Boys							Girls							B+G	
	0	1-4	5-9	-14	-19	Tot	%	0	1-4	5-9	-14	-19	Tot	%	No	%
<u>I Leukemias, myeloproliferative diseases</u>	<u>0</u>	<u>30</u>	<u>15</u>	<u>13</u>	<u>34</u>	<u>92</u>	<u>42.4</u>	<u>0</u>	<u>15</u>	<u>7</u>	<u>8</u>	<u>15</u>	<u>45</u>	<u>35.2</u>	<u>137</u>	<u>39.7</u>
1(a) Lymphoid leukemias	0	25	11	6	14	56	25.8	0	13	7	5	7	32	25.0	88	25.5
1(b) Acute myeloid leukemias	0	4	4	2	9	19	8.8	0	2	0	2	7	11	8.6	30	8.7
1(c) Chronic myeloproliferative diseases	0	0	0	4	10	14	6.5	0	0	0	1	1	2	1.6	16	4.6
1(e) Unspecified and other specified leukemias	0	1	0	1	1	3	1.4	0	0	0	0	0	0	0.0	3	0.9
<u>II Lymphomas and reticuloendothelial neoplasms</u>	<u>0</u>	<u>0</u>	<u>9</u>	<u>8</u>	<u>11</u>	<u>28</u>	<u>12.9</u>	<u>0</u>	<u>0</u>	<u>3</u>	<u>3</u>	<u>4</u>	<u>10</u>	<u>7.8</u>	<u>38</u>	<u>11.0</u>
2(a) Hodgkin lymphomas	0	0	5	6	8	19	8.8	0	0	2	1	2	5	3.9	24	7.0
2(b) Non-Hodgkin lymphomas	0	0	3	1	3	7	3.2	0	0	0	1	2	3	2.3	10	2.9
2(c) Burkitt lymphoma	0	0	0	1	0	1	0.5	0	0	1	0	0	1	0.8	2	0.6
2(d) Miscellaneous lymphoreticular neoplasms	0	0	0	0	0	0	0.0	0	0	0	1	0	1	0.8	1	0.3
2(e) Unspecified lymphomas	0	0	1	0	0	1	0.5	0	0	0	0	0	0	0.0	1	0.3
<u>III CNS & misc intracranial & intraspinal Neoplasms</u>	<u>0</u>	<u>3</u>	<u>3</u>	<u>1</u>	<u>1</u>	<u>8</u>	<u>3.7</u>	<u>0</u>	<u>2</u>	<u>4</u>	<u>1</u>	<u>2</u>	<u>9</u>	<u>7.0</u>	<u>17</u>	<u>4.9</u>
3(a) Ependymomas and choroid plexus tumor	0	2	2	0	0	4	1.8	0	2	3	1	0	6	4.7	10	2.9
3(b) Astrocytomas	0	1	0	0	1	2	0.9	0	0	1	0	1	2	1.6	4	1.2
3(c) Intracranial and intraspinal embryonal tumors	0	0	1	0	0	1	0.5	0	0	0	0	0	0	0.0	1	0.3
3(d) Other gliomas	0	0	0	1	0	1	0.5	0	0	0	0	1	1	0.8	2	0.6
<u>IV Neuroblastoma & oth peripheral nervous cell</u>	<u>0</u>	<u>5</u>	<u>2</u>	<u>0</u>	<u>0</u>	<u>7</u>	<u>3.2</u>	<u>0</u>	<u>2</u>	<u>1</u>	<u>0</u>	<u>0</u>	<u>3</u>	<u>2.3</u>	<u>10</u>	<u>2.9</u>
4(a) Neuroblastoma and ganglioneuroblastoma	0	5	2	0	0	7	3.2	0	2	1	0	0	3	2.3	10	2.9
<u>V Retinoblastoma</u>	<u>0</u>	<u>2</u>	<u>1</u>	<u>0</u>	<u>0</u>	<u>3</u>	<u>1.4</u>	<u>0</u>	<u>1</u>	<u>0</u>	<u>0</u>	<u>0</u>	<u>1</u>	<u>0.8</u>	<u>4</u>	<u>1.2</u>
5 Retinoblastoma	0	2	1	0	0	3	1.4	0	1	0	0	0	1	0.8	4	1.2
<u>VI Renal tumors</u>	<u>0</u>	<u>5</u>	<u>0</u>	<u>0</u>	<u>1</u>	<u>6</u>	<u>2.8</u>	<u>1</u>	<u>1</u>	<u>2</u>	<u>0</u>	<u>1</u>	<u>5</u>	<u>3.9</u>	<u>11</u>	<u>3.2</u>
6(a) Nephroblastoma & oth nonepithelial renal	0	4	0	0	1	5	2.3	0	1	2	0	0	3	2.3	8	2.3
6(b) Renal carcinomas	0	1	0	0	0	1	0.5	0	0	0	0	0	0	0.0	1	0.3
6(c) Unspecified malignant renal tumors	0	0	0	0	0	0	0.0	1	0	0	0	1	2	1.6	2	0.6
<u>VII Hepatic tumors</u>	<u>0</u>	<u>2</u>	<u>0</u>	<u>0</u>	<u>1</u>	<u>3</u>	<u>1.4</u>	<u>0</u>	<u>1</u>	<u>1</u>	<u>0</u>	<u>0</u>	<u>2</u>	<u>1.6</u>	<u>5</u>	<u>1.4</u>
7(a) Hepatoblastoma	0	2	0	0	0	2	0.9	0	1	1	0	0	2	1.6	4	1.2
7(b) Hepatic carcinomas	0	0	0	0	1	1	0.5	0	0	0	0	0	0	0.0	1	0.3
<u>VIII Malignant bone tumors</u>	<u>0</u>	<u>7</u>	<u>4</u>	<u>16</u>	<u>17</u>	<u>44</u>	<u>20.3</u>	<u>2</u>	<u>2</u>	<u>6</u>	<u>9</u>	<u>11</u>	<u>30</u>	<u>23.4</u>	<u>74</u>	<u>21.4</u>
8(a) Osteosarcomas	0	2	4	9	10	25	11.5	0	2	3	7	7	19	14.8	44	12.8
8(b) Chondrosarcomas	0	0	0	1	1	2	0.9	0	0	0	0	0	0	0.0	2	0.6
8(c) Ewing tumor and related sarcomas of bone	0	5	0	6	6	17	7.8	2	0	3	2	3	10	7.8	27	7.8
8(d) Other specified malignant bone tumors	0	0	0	0	0	0	0.0	0	0	0	0	1	1	0.8	1	0.3
<u>IX Soft tissue and other extraosseous sarcomas</u>	<u>0</u>	<u>3</u>	<u>2</u>	<u>2</u>	<u>6</u>	<u>13</u>	<u>6.0</u>	<u>0</u>	<u>3</u>	<u>0</u>	<u>4</u>	<u>2</u>	<u>9</u>	<u>7.0</u>	<u>22</u>	<u>6.4</u>
9(a) Rhabdomyosarcomas	0	2	2	0	0	4	1.8	0	1	0	1	1	3	2.3	7	2.0
9(b) Fibrosarcomas, peripheral nerve sheath	0	1	0	0	1	2	0.9	0	0	0	0	0	0	0.0	2	0.6
9(d) Other specified soft tissue sarcomas	0	0	0	1	3	4	1.8	0	0	0	2	1	3	2.3	7	2.0
9(e) Unspecified soft tissue sarcomas	0	0	0	1	2	3	1.4	0	2	0	1	0	3	2.3	6	1.7
<u>X Germ cell tumors, trophoblastic tumors</u>	<u>0</u>	<u>0</u>	<u>1</u>	<u>0</u>	<u>2</u>	<u>3</u>	<u>1.4</u>	<u>0</u>	<u>3</u>	<u>0</u>	<u>0</u>	<u>5</u>	<u>8</u>	<u>6.3</u>	<u>11</u>	<u>3.2</u>
10(a) Intracranial and intraspinal germ cell tumors	0	0	1	0	0	1	0.5	0	0	0	0	0	0	0.0	1	0.3
10(b) Malignant extracranial and extragonadal	0	0	0	0	1	1	0.5	0	2	0	0	1	3	2.3	4	1.2
10(c) Malignant gonadal germ cell tumors	0	0	0	0	1	1	0.5	0	1	0	0	3	4	3.1	5	1.4
10(e) Other and unspecified malignant gonadal	0	0	0	0	0	0	0.0	0	0	0	0	1	1	0.8	1	0.3
<u>XI Oth malig epithelial neoplasms & malig</u>	<u>0</u>	<u>0</u>	<u>0</u>	<u>2</u>	<u>6</u>	<u>8</u>	<u>3.7</u>	<u>0</u>	<u>0</u>	<u>0</u>	<u>0</u>	<u>5</u>	<u>5</u>	<u>3.9</u>	<u>13</u>	<u>3.8</u>
11(b) Thyroid carcinomas	0	0	0	1	1	2	0.9	0	0	0	0	1	1	0.8	3	0.9
11(c) Nasopharyngeal carcinomas	0	0	0	0	1	1	0.5	0	0	0	0	0	0	0.0	1	0.3
11(f) Other and unspecified carcinomas	0	0	0	1	4	5	2.3	0	0	0	0	4	4	3.1	9	2.6
<u>XII Other and unspecified malignant neoplasms</u>	<u>0</u>	<u>1</u>	<u>0</u>	<u>0</u>	<u>1</u>	<u>2</u>	<u>0.9</u>	<u>0</u>	<u>0</u>	<u>0</u>	<u>1</u>	<u>0</u>	<u>1</u>	<u>0.8</u>	<u>3</u>	<u>0.9</u>
12(b) Other unspecified malignant tumors	0	1	0	0	1	2	0.9	0	0	0	1	0	1	0.8	3	0.9
Total	0	58	37	42	80	217	100.0	3	30	24	26	45	128	100.0	345	100.0